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Background: Asthma exacerbations affect the quality of life of patients with asthma and have a major
effect on the overall costs of asthma care. An asthma self-management plan that advises the temporary
quadrupling of inhaled corticosteroid dose may prevent asthma exacerbations, but this needs to be
confirmed before being adopted widely.
Objectives: To compare the clinical effectiveness and cost-effectiveness of an asthma self-management
plan that advises patients to temporarily quadruple the dose of inhaled corticosteroid when asthma control
starts to deteriorate with a standard self-management plan.
Design: A multicentre, parallel-group, pragmatic randomised trial, with follow-up for 12 months.
Setting: Primary and secondary care across 207 sites in the UK.
Participants: Asthma patients aged ≥ 16 years treated with an inhaled corticosteroid who had
experienced at least one exacerbation in the previous 12 months.
Interventions: Participants were randomised (1 : 1) to a usual-care self-management plan or to a modified
self-management plan that advised a temporary quadrupling of the inhaled corticosteroid at the point of
asthma deterioration, both of which were actively implemented and supported by local research staff.
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Primary outcome: The primary outcome of ‘time to first asthma exacerbation’ was defined as the need
for systemic corticosteroids (for at least 3 consecutive days) and/or unscheduled health-care consultations
for asthma (i.e. reaching zone 3 or 4 of the Asthma UK self-management plan).
Results: A total of 1922 participants were randomised: the primary analysis included 938 participants
(97%) in the usual-care group and 933 participants (97%) in the modified self-management group. The
number of participants having at least one exacerbation of asthma in the year after randomisation was
484 (51.6%) in the usual-care group and 420 (45.0%) in the modified self-management group [adjusted
hazard ratio 0.81, 95% confidence interval (CI) 0.71 to 0.92; p = 0.002]. There were fewer serious
adverse events reported in the modified self-management group than in the usual-care group (11 vs. 32,
respectively). Eight and six events of pneumonia, lower respiratory tract infections or influenza were
reported in the usual-care group and the modified self-management group, respectively. Health-care-
related costs were lower in the modified self-management group. The modified self-management group
was £24 (bootstrapped 95% CI –£122 to £71) less costly than usual care, with a greater quality-adjusted
life-year gain of 0.02 (bootstrapped 95% CI –0.005 to 0.04). Therefore, the modified self-management
group was ‘dominant’, with a 94–95% probability of being cost-effective at the £20,000–30,000 threshold.
Limitations: As the Fourfold Asthma STudy (FAST) was an open-label pragmatic trial, the possibility of
treatment bias that may have affected the participants in the modified self-management group cannot be
ruled out. Poorer than expected completion of participant diary cards, particularly within the usual-care
self-management group, could have led to a null bias, underestimating the true effect of the intervention.
Conclusions: An asthma self-management plan that advises patients to temporarily quadruple their dose of
inhaled corticosteroid at the point of asthma symptoms worsening does reduce clinically important asthma
exacerbations. In addition, the plan is cost-effective compared with the usual-care self-management plan.
Future work: To effectively implement asthma self-management plans that advise a temporary
quadrupling of inhaled steroid at asthma deterioration into routine practice.
Trial registration: Current Controlled Trials ISRCTN15441965.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 70. See the NIHR Journals Library website
for further project information.
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Plain English summary
Asthma is one of the commonest long-term diseases worldwide. Asthma attacks are characterised byworsening of asthma symptoms (such as coughing and shortness of breath) and sometimes require
treatment with oral steroid tablets, which are unpopular because they can cause severe side effects.
It is widely believed that using asthma self-management plans can reduce asthma attacks and help people
get on with their lives. The previous study suggested that a self-management plan that included a temporary
fourfold increase in the use of their steroid inhaler when asthma symptoms were increasing was good at
reducing asthma attacks; however, a larger study was needed to be sure of the results.
The Fourfold Asthma STudy (FAST) tested whether or not an asthma self-management plan that advised a
temporary fourfold increase in the use of the steroid inhaler when asthma symptoms started to worsen
could prevent asthma attacks. A total of 1922 people with asthma took part in the study and a computer
was used to decide whether participants received the trial self-management plan or usual care. Participants
were asked to attend visits at 6 and 12 months as well as any time their asthma started to worsen to
assess the impact of the plan.
The trial self-management plan was given to 957 participants, of whom 562 experienced worsening asthma
symptoms. The participants who increased their inhaled steroid dose fourfold saw a reduction in the number
of asthma attacks compared with the usual-care group, by about 20%.
Overall, the trial suggested that a temporary fourfold increase in inhaled steroid at the point at which
asthma worsened reduced asthma attacks. The fourfold increase in inhaled steroid also reduced reported
emergency general practitioner/hospital visits and the number of steroid tablets prescribed per participant
and, overall, was better value for money. Approximately 15 people with asthma need to be taught to use
such a plan to prevent one severe attack.
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Scientific summary
Extracts of text throughout this Scientific summary have been published in Skeggs et al. [Skeggs A,McKeever T, Duley L, Mitchell E, Bradshaw L, Mortimer K, et al. Fourfold Asthma Study (FAST): a study
protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling
the dose of inhaled steroid to prevent asthma exacerbations. Trials 2016;17:499. URL: https://trialsjournal.
biomedcentral.com/articles/10.1186/s13063-016-1608-6]. This is an open access article distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution and reproduction in any medium, provided the original work
is properly cited.
Background
Asthma is a chronic long-term condition estimated to affect 300 million people worldwide. Acute
exacerbations of asthma are unpredictable, disruptive and frightening. The acute exacerbations cause
considerable morbidity and account for a large proportion of the health service costs of asthma. The
widespread use of an asthma self-management plan, designed to encourage disease monitoring and
timely intervention, can reduce exacerbations and such plans are internationally recommended for all
patients with asthma. Unfortunately, the majority of patients are not provided with a plan. There are a
variety of reasons for this but uncertainty about what to include in the plan when asthma control is
deteriorating but before the need for systemic corticosteroids is a contributing factor.
The aim of this trial was to determine whether or not an asthma self-management plan that included a
temporary quadrupling of the dose of inhaled corticosteroid when asthma control started to deteriorate
can reduce severe asthma exacerbations requiring systemic corticosteroids or an unscheduled health-care
consultation for asthma compared with a standard self-management plan.
Objectives
Overall, the study assessed the comparative clinical effectiveness and cost-effectiveness of an asthma
self-management plan that includes a temporary quadrupling of the dose of inhaled corticosteroid when
asthma control starts to deteriorate at preventing an asthma exacerbation. Asthma exacerbation was
defined as the need for systemic corticosteroids and/or an unscheduled health-care consultation for asthma.
The primary objective was to determine whether or not the proposed asthma self-management plan
reduces asthma exacerbations.
The secondary objectives were to determine (1) whether or not the proposed asthma self-management
plan reduces the deterioration in asthma control and (2) if the proposed asthma self-management plan is
cost-effective to the NHS and society overall.
Methods
Study design
A multicentre, parallel-group, pragmatic randomised trial, with follow-up for 12 months. Adults were
randomised (1 : 1) to follow either a usual-care self-management plan or a modified asthma self-management
plan, which includes a temporary fourfold increase in inhaled corticosteroid when asthma control starts
to deteriorate.
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Recruitment
Participants were recruited from both primary and secondary care across England and Scotland, and
through local advertising. Most participants (approximately 80%) were recruited within primary care.
Primary care recruitment was in general practices across England and Scotland in conjunction with Primary
Care Research Networks [subsequently local Clinical Research Networks (CRNs)/Scottish CRNs], with
practices acting either as Participant Identification Centres or as Research Initiative Sites (RISs). Participants
were identified by database searches and invitation letters and by opportunistic recruitment via posters,
social media and face-to-face discussions.
Secondary care recruitment was primarily from respiratory outpatient clinics and via specific research
volunteer databases.
Eligibility
Inclusion criteria
Patients were considered eligible for entry into the trial if the following inclusion criteria were met:
l men or women aged ≥ 16 years
l clinician-diagnosed asthma treated with a licensed dose of inhaled corticosteroid [i.e. steps 2–4 of the
British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines]
l one or more asthma exacerbations in the last 12 months requiring treatment with systemic corticosteroids
l current smokers could be included provided that the recruiting centres had good evidence of underlying
asthma (i.e. a life-long history of asthma, a > 12% forced expiratory volume in 1 second (FEV1)
reversibility, or sputum or blood eosinophilia).
Exclusion criteria
l A history more in keeping with smoking-related chronic obstructive pulmonary disease (i.e. smoked
> 20 pack-years, without evidence of significant reversibility or blood eosinophilia).
l On maintenance systemic corticosteroids (i.e. step 5 of the BTS/SIGN guidelines).
l Using a combination inhaler for both maintenance and relief treatment.
l Experienced an exacerbation within 4 weeks of randomisation.
l Women who were pregnant, breastfeeding or who were planning to become pregnant.
Interventions
Participants were randomised equally (i.e. 1 : 1) to one of two asthma self-management plans
(usual or modified) developed from the Asthma UK plan [Asthma UK. Asthma UK Asthma Action Plan.
URL: www.asthma.org.uk/globalassets/health-advice/resources/adults/adult-asthma-action-plan.pdf
(accessed 14 July 2017)] that was in use at the time of protocol development. In both the usual-care and
modified plans, zones 1, 3 and 4 were identical and zone 2 included the current area of uncertainty and
the research question under investigation.
At randomisation, participants were provided with asthma diary cards, which were to be completed for
14 days when their asthma deteriorated. On reaching zone 2 of the plan, the usual-care group were advised
to increase their bronchodilator medication, as per current recommendations, for a maximum of 14 days,
and the modified self-management group were advised to increase their bronchodilators and quadruple
their inhaled corticosteroid dose.
Assessment of adherence to the two self-management plans included a review of the asthma diary card
and questions about whether or not and how participants changed their inhaled corticosteroid treatment
since activating zone 2 of their self-management plan (e.g. total number of puffs per inhaler, morning peak
expiratory flow score, requirement for systemic corticosteroids).
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Outcomes
The primary outcome of ‘time to first asthma exacerbation’ was defined as the need for systemic corticosteroids
(for at least 3 consecutive days) and/or unscheduled health-care consultations for asthma (i.e. reaching zone 3
or 4 of the Asthma UK self-management plan).
Secondary outcomes included the use of systemic corticosteroids and unscheduled health-care consultations
for an acute exacerbation of asthma (number of participants and total number of courses of systemic
corticosteroids, unscheduled health-care consultations and exacerbations; time to participants requiring
systemic corticosteroids and time to an unscheduled health-care consultation for an acute exacerbation of
asthma), cumulative dose of inhaled and systemic corticosteroids used in the 12 months after randomisation,
area under the morning peak flow curve over 2 weeks after activating zone 2 of the self-management plan
and Juniper et al.’s (Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the
Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32–8) Asthma Quality of Life Questionnaire
(Mini AQLQ). The cost and resource outcomes of both trial arms are reported as incremental cost per asthma
exacerbation prevented and cost per quality-adjusted life-year (QALY) gained.
Sample size
With 2300 participants and using a log-rank test (at the two-sided 5% significance level), the study had at
least 90% power to detect a difference of 30% (relative effect), assuming an exacerbation rate of 13% in
the control group and allowing for loss to follow-up of around 15%. A 13% exacerbation rate requiring
systemic corticosteroids, was the lowest level seen in the control group of previous studies of this type and
so provided a conservative estimate.
Owing to the interim event rate for the primary outcome being higher than estimated, the power calculation
was revised in March 2015. Assuming an exacerbation rate in the control group of 17%, 90% power and
still estimating a one-third reduction in the modified self-management group, the sample size was revised to
between 1750 and 1850 participants, allowing for loss to follow-up.
Randomisation and blinding
Randomisation was stratified by recruiting site (20 regional centres), smoking status (yes/no) and maintenance
dose of inhaled corticosteroid dose (high/low).
This was an open-label clinical trial, so the participant and local study team were aware of the self-management
plan allocation. Prior to database lock only the Data Monitoring Committee was able to review data according to
treatment allocation, whereas the blinding allocation was preserved for the chief investigator, trial statisticians,
the Nottingham Clinical Trials Unit trial management team and the Trial Steering Committee members.
Statistical methods
All analyses were based on the intention-to-treat principle, for example analysed as randomised regardless
of adherence to a self-management plan. All participants were included in the analysis of the primary
outcome apart from those with no further contact after randomisation, and for whom, therefore,
information about oral corticosteroid use or unscheduled health-care consultations for asthma was
unavailable. Cox proportional hazards regression model adjusting for randomisation stratification variables
was used to analyse the primary outcome. Subgroup analyses, for smoking status at trial entry and high/low
levels of inhaled corticosteroid use at trial entry, were also performed by including an interaction term in the
Cox proportional hazards model.
Health economics
A cost-effectiveness analysis was undertaken to compare the modified self-management plan with the
usual-care self-management plan. Following the National Institute for Health and Care Excellence’s guidelines,
the analysis was conducted from the NHS and Personal Social Services perspectives, with costs expressed in
Great British pounds for the financial year 2014–15. QALYs were estimated by calculating the area under the
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curve, using utility scores measured by EuroQol-5 Dimensions, three-level version (EQ-5D-3L), questionnaires
at baseline, and at the 6-month and 12-month follow-ups. As well as QALYs, the economic evaluation also
determined cost-effectiveness results based on the total number of exacerbations per participant in the
12-month period.
The level of uncertainty associated with the decision over which option was most cost-effective was
explored using the non-parametric bootstrapping method and presented using cost-effectiveness planes
and cost-effectiveness acceptability curves.
Results
Recruitment to the study took place between 17 May 2013 and 29 January 2016. During this time, in
excess of 20,695 patients were contacted and, subsequently, 4811 patients were assessed for eligibility.
Of these 4811 patients, 1922 (40%) were randomised: 965 to usual self-management and 957 to the
modified self-management.
Characteristics at baseline were well balanced between the two treatment groups.
The mean age of participants was 57 years [standard deviation (SD) 15 years] and 1305 (68%) were
women. At trial entry, 1344 participants (70%) were using a combination inhaler and 1495 (78%)
were classed as being on a low dose of steroids (i.e. ≤ 1000 mcg/day of beclometasone dipropionate).
Primary outcome
There were 938 (97%) participants in the usual-care group and 933 (97%) participants in the modified
treatment group included in the analysis of the primary outcome. A total of 27 participants from the
usual-care self-management group and 24 from the modified self-management group were excluded from
the analysis because they withdrew consent on the day of randomisation or they experienced exacerbation
on the day of randomisation or no further information was available following randomisation. The number
of participants having an exacerbation of asthma in the year after randomisation was 484 (51.6%) in the
usual-care group and 420 (45.0%) in the modified self-management group. The adjusted hazard ratio for
the time to first asthma exacerbation in the modified self-management group compared with the usual-care
group was 0.81 [95% confidence interval (CI) 0.71 to 0.92; p = 0.002].
There was no evidence of a difference in the hazard ratio for time to asthma exacerbation in the modified
self-management group compared with the usual-care group according to smoking status or dose of
maintenance inhaled steroid dose at baseline.
Secondary outcome
The number of participants using systemic corticosteroids [adjusted risk difference (RD) –7.0%, 95% CI
–11.3% to –2.7%], having an unscheduled health-care consultation (RD –6.8%, 95% CI –11.1% to
–2.4%) and an exacerbation (systemic corticosteroids or an unscheduled health-care consultation,
RD –6.7%, 95% CI –11.2% to –2.3%) was lower in the modified self-management group than in the
usual-care group.
Similarly, the total number of courses of systemic corticosteroids [adjusted incidence rate ratio (IRR) 0.82,
95% CI 0.70 to 0.96], unscheduled health-care consultations (adjusted IRR 0.86, 95% CI 0.75 to 0.99)
and exacerbations (adjusted IRR 0.88, 95% CI 0.77 to 1.01) per participant was lower in the modified
self-management group than in the usual-care group.
Safety outcome
The usual-care group experienced a higher incidence of serious adverse events (SAEs) than the modified
self-management group, with 22 participants (4%) in the usual-care group and 11 participants (2%) in the
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modified self-management group who activated zone 2 or above experiencing at least one SAE. Eighteen
of the 32 SAEs in the usual-care group were as a result of hospitalisations for asthma, compared with
3 of the 11 SAEs in the modified self-management group. Eight and six events of pneumonia, lower
respiratory tract infections or influenza were reported as SAEs in the usual-care group and the modified
self-management group, respectively.
More incidents of known side effects of inhaled corticosteroids were reported by the participants in the
modified self-management group [collected as adverse events (AEs)]. Ten participants in the usual-care group
(2%) and 41 participants in the modified self-management group (7%) who activated zone 2 or above had
at least one known adverse effect of inhaled corticosteroids, such as oral candidiasis and dysphonia. Of the
56 non-serious AEs in the modified self-management group, 44 were classified as definitely or probably
related to inhaled corticosteroids, compared with 6 of the 13 non-serious AEs in the usual-care group.
Health economic outcome
The modified self-management group had a lower total reported cost per participant than the usual-care
group (£415 vs. £431, respectively); this was mostly driven by the difference in health-care resource use.
This resulted in modified self-management being £24 (bootstrapped 95% CI –£122 to £71) less costly
than usual care; however, this difference did not reach statistical significance (p = 0.681).
There was little difference between the QALY scores for the two groups at baseline, and both groups’
scores declined over the duration of the study period. The resulting difference in the QALY was 0.02
(bootstrapped 95% CI –0.005 to 0.04) greater for the modified self-management group after adjusting
for baseline EQ-5D-3L scores; however, this difference was not statistically significant (p = 0.207).
The mean number of exacerbations was also lower in the modified self-management group [0.84 exacerbations,
standard error (SE) = 0.04] than in the usual self-management group (0.95 exacerbations, SE = 0.04) with
an adjusted difference of 0.10 (bootstrapped 0.95% CI –0.22 to 0.01) exacerbations. As the modified
treatment was both less costly and more effective for both health outcomes, the modified treatment was
said to be ‘dominant’. This was supported by the uncertainty analysis showing a 94–95% probability of the
modified treatment being cost-effective at the £20,000–30,000 threshold.
Conclusions
Implications for health care
The trial has demonstrated that a temporary quadruple increase in the dose of inhaled corticosteroid at the
point when asthma control starts to deteriorate can prevent severe asthma exacerbations when compared
with the usual-care self-management plan. A temporary quadrupling, rather than usual self-management,
is also associated with fewer unscheduled health-care consultations, courses of prescribed systemic
corticosteroids and reported asthma-related hospitalisations.
The economic analysis found that participants who received the modified treatment had, after adjusting
for covariates, non-significantly lower total mean costs over the 12-month period. The evidence showed
that quadrupling the inhaled corticosteroid dose at the point of asthma worsening did result in better
clinical outcomes and was supported by the economic analysis.
Recommendations for practice
The trial has shown that the use of an asthma self-management plan that advises patients to quadruple their
dose of inhaled corticosteroid at the point of asthma deterioration is effective in reducing exacerbations and
should be considered by clinical commissioners as being embedded into routine general practice for asthma
patients who exacerbated in the last year. It was calculated that 15 patients need to be taught to use such a
plan to prevent one exacerbation or unscheduled health-care consultation.
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Trial registration
This trial is registered as ISRCTN15441965.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Extracts of text, figures and tables throughout this chapter have been published in Skeggs et al.1This is an open access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution and reproduction
in any medium, provided the original work is properly cited.
Background
Asthma is one of the commonest chronic diseases in the world, affecting an estimated 300 million people.
Acute exacerbations of asthma cause considerable morbidity and account for a large component of the
direct and indirect costs of asthma.
Previous studies have shown that the widespread use of an asthma self-management plan can reduce
exacerbations requiring oral corticosteroids and emergency health-care utilisation, as well as reduce time
away from work or school because of poorly controlled asthma. However, although written self-management
plans are recommended for all patients with asthma, many patients are not provided with one. Reasons for
not being provided with a self-management plan include a lack of time and confusion about what to include
in the plan when asthma control is deteriorating but before there is a need for oral corticosteroids.
Two large randomised, double-blind, placebo-controlled clinical trials2,3 found no benefit from doubling the
dose of a patient’s usual inhaled corticosteroid2 or doubling the dose of inhaled budesonide3 when asthma
control starts to deteriorate. However, other studies have suggested that higher doses (e.g. a fivefold
increase4 or 1 mg of inhaled fluticasone propionate twice daily5) may be effective for the treatment of
established exacerbations. A previous single-centre, randomised, double-blind, placebo-controlled clinical
trial carried out by the chief investigator explored whether or not asthma exacerbations could be prevented
with a self-management plan that recommended quadrupling the dose of inhaled corticosteroid at the time
when asthma control starts to deteriorate (n = 403).6 The results showed that for those participants who
started on the study inhalers (n = 94) quadrupling the dose of inhaled corticosteroid led to a 36% reduction
in asthma exacerbations (per-protocol analysis, p = 0.004). Unfortunately, the number of participants starting
on the study inhaler varied between the two groups and the primary outcome in the intention-to-treat
analysis was not significant. There is no evidence to suggest that a higher dose (i.e. a fivefold increase) is any
more effective and would be associated with greater systemic activity.
In view of the limited evidence for quadrupling the dose of inhaled steroid at the point when asthma control
starts to deteriorate, the UK National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) programme issued a funding call in February 2010 and, subsequently, commissioned the Fourfold
Asthma Study (FAST) (reference number 10/143/01).
Objectives
Primary objective
l Determine whether or not the proposed asthma self-management plan reduces asthma exacerbations
requiring oral steroids or unscheduled health-care consultations for asthma, compared with the usual
self-management plan.
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Secondary objectives
l Determine whether or not the proposed asthma self-management plan reduces the deterioration in
asthma control, compared with the usual self-management plan.
l Determine if the proposed asthma self-management plan is cost-effective to the NHS and society
overall, compared with the usual self-management plan.
Role of the funder
The study was funded by the NIHR HTA programme. The NIHR had input into the trial design through peer
review of the proposal, but did not have a role in data collection, data analysis, data interpretation or the
writing of the final report. The corresponding author had access to all the data and was responsible for the
decision to submit the final report.
INTRODUCTION
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Chapter 2 Methods
Extracts of text, figures and tables throughout this chapter have been published in Skeggs et al.1and in the International Standard Registered Clinical/soCial sTudy Number (ISRCTN) Registry as
ISRCTN15441965.7 These are open access articles distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution
and reproduction in any medium, provided the original work is properly cited.
Trial design
The FAST was a multicentre, pragmatic, normal care-controlled, randomised controlled trial (RCT) of 12 months’
duration (Figure 1). Adult asthma patients were randomised (1 : 1) to one of two asthma self-management
plans: usual care or modified. Both self-management plans were identical at zones 1, 3 and 4, but at zone 2
(worsening of asthma symptoms) the usual-care group was advised to follow the current guidelines of increasing
bronchodilator medication when asthma control begins to deteriorate. The modified self-management plan
advised participants to increase bronchodilator medication and quadruple their inhaled corticosteroid dose.
Both self-management plans advised participants to increase their medication for a maximum of 14 days, or for a
shorter duration if asthma symptoms started to improve, before returning to their normal treatment, which was
actively promoted in both self-management plans.
Invited to participate
Visit 1
Eligibility assessment,
consent and randomisation
Usual care
(n = 965)
Modified (fourfold)
(n = 957)
Scheduled visit 6 months
after visit 1
Visit to attend clinic up to
14 days following
activation of zone 2
Scheduled visit 12 months
after visit 1
Visit 2
Visit 3
Post-activation visit
FIGURE 1 Trial visit flow chart.
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Participants were expected to attend three scheduled visits: baseline, 6 months and 12 months. These visits
were conducted at the participants’ local general practitioner (GP)’s clinic or hospital (or via the telephone
if easier for the participant). During these visits the research nurse reviewed the participant’s diary card to
assess their adherence to the self-management plan and use of inhaled steroids, reviewed the participant’s
asthma control to determine if there had been any unreported activation of zones 2, 3 or 4 since the
previous visit and asked participants to complete the EuroQol-5 Dimensions, three-level version (EQ-5D-3L),
questionnaire and Service Use Questionnaire (see Appendix 1).
In addition to the scheduled visits, participants were expected to attend post-activation visits no less than
14 days after activating zone 2 of the asthma self-management plan; for some participants multiple visits took
place in the 12-month participation period. Prior to the visit participants were expected to complete a diary
card. For FAST two diary cards were used: one diary card for those participants who used corticosteroid inhalers
and a second for those on combination inhalers. The participants used the diary cards to record peak flow,
to record the asthma medication used to manage symptoms (including the number of puffs of usual preventer
inhaler, of extra corticosteroid inhaler and of reliever inhaler and whether or not any systemic corticosteroids
were taken) and to document whether they had an asthma-related GP or hospital appointment. The diary cards
acted as an aide-memoire during the post-activation visit; the research nurse reviewed the daily peak flow
measurements, any health-care consultations attended, the use of inhaled corticosteroids and systemic
corticosteroids, ascertained if any adverse events (AEs) had occurred and assessed the participant’s adherence
to the asthma self-management plan. Participants were also asked to complete the Juniper et al.Mini Asthma
Quality of Life Questionnaire (Mini AQLQ).8 The study assessments are outlined in Table 1.
TABLE 1 Study assessments
Study assessments
Named trial visit
Visit 1/
screening
Activation
of zone 2
(days 0–14)
Post-activation
visit (14 days)a
Visit 2 (6 months
after visit 1)
Visit 3 (12 months
after visit 1)
Demographics/eligibility,
consent
✓
Randomisation ✓
Asthma diary card
completionb
✓
Mini AQLQc ✓ ✓
Issue asthma diary card ✓ ✓
EQ-5D-3Ld ✓ ✓ ✓
Service Use Questionnairee ✓ ✓
Adherence to the
self-management planf
✓ ✓ ✓
Asthma diary card review ✓
Asthma review ✓ ✓
a Participants were expected to attend the clinic up to 14 days after activating zone 2 of the asthma self-management plan
or as soon as convenient thereafter.
b The asthma diary card completion was required, where possible, for 14 days.
c The Mini AQLQ was completed by the participant.
d The EQ-5D-3L questionnaire was completed by the participant.
e The Service Use Questionnaire was administered by a member of the study team.
f Adherence was self-reported by participant.
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In addition, it was planned that the first 200 participants recruited at the Nottingham and Liverpool sites
would have the option (if they agreed) to have their inhaled corticosteroid inhaler fitted with a smart
inhaler electronic dose counter for adherence purposes. The main purpose of this was to compare an
electronic record of inhaler use with the participants’ self-reported inhaler use and, therefore, the overall
adherence to their allocated self-management plan. The smart inhaler was planned to be used to
independently validate the accuracy of the participants’ self-reported adherence.
The implementation of the smart inhaler was challenging and, unfortunately, some technical issues
(the smart inhaler not working correctly and a short battery life) prevented the implementation of the
initial batch of devices into the trial.
Following a period of uncertainty around delivery and the reliability of new devices to replace those that
did not function accurately, it was the unanimous view of the Trial Steering Committee (TSC), at a meeting
held in July 2014, that it was not practical to pursue further use of monitoring devices as the chance of
any informative data being obtained from them prior to the end of the study was low. As a result, the
planned interim analysis to determine whether or not self-reported adherence to adjustments to inhaled
steroid dose was similar to that captured by the electronic devices was not conducted.
Recruiting centres
Recruitment took place in both primary and secondary care across England and Scotland. There were
10 secondary care sites: Nottingham City Hospital, Leicester Glenfield Hospital, Freeman Hospital Newcastle,
Aintree University Hospital, Aberdeen Royal Infirmary, Royal Liverpool University Hospital, King’s Mill Hospital,
Arrowe Park Hospital, Blackpool Victoria Hospital and Bradford Royal Infirmary. In addition, there were
171 primary care Research Initiative Sites (RISs) across 11 CRN regions: North East and North Cumbria,
North West Coast, Greater Manchester, East Midlands, West Midlands, West of England, Thames Valley
and South Midlands, Eastern, Kent, Surrey, Sussex, Wessex and South West Peninsula.
Participants were identified through secondary care and primary care. In secondary care, participants were
identified from patients attending respiratory outpatient appointments at the individual recruiting centres
and also through running database searches of participants who had previously participated in asthma
studies and had given consent to be contacted again for future studies. In Scottish centres, the Scottish
Primary Care Research Network identified potential participants in primary care who were subsequently
recruited at local secondary care sites. In primary care, local CRNs liaised directly with GP practices that
acted as RISs that performed a database search to identify potential participants. Potentially eligible
participants were sent a participation invitation pack that included an invitation letter flyer about the trial
and, in some practices, a copy of the Participant Information Sheet.
A local press release was issued at the start of the trial. Posters and flyers were displayed in recruiting centres
and, where possible, a digital flyer was displayed in recruiting centre waiting areas. Posters were also displayed
in pharmacies in the Nottinghamshire area and information flyers were placed in the bags of patients who
were collecting prescriptions for asthma medication. The trial was also promoted online by Asthma UK.
General practitioner surgeries local to the recruiting hospitals were used as Participant Information Centres
(PICs) by displaying posters and flyers.
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Participants
Patients were considered eligible for entry into the trial if the following inclusion criteria were met:
l men or women aged ≥ 16 years
l clinician-diagnosed asthma treated with a licensed dose of inhaled corticosteroid [i.e. steps 2–4
of the British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN) guidelines]2
l one or more exacerbations in the last 12 months requiring treatment with systemic corticosteroids
l current smokers could be included provided that the recruiting centres had good evidence of
underlying asthma (i.e. a life-long history of asthma, a > 12% forced expiratory volume in 1 second
(FEV1) reversibility, or sputum or blood eosinophilia).
In addition, patients were not entered into the trial if any of the following exclusions applied:
l a history more in keeping with smoking-related chronic obstructive pulmonary disease (COPD)
(i.e. smoked > 20 pack-years, without evidence of significant reversibility or eosinophilia)
l on maintenance systemic corticosteroids (i.e. step 5 of the BTS/SIGN guidelines2)
l using a combination inhaler for both maintenance and relief treatment
l experienced an exacerbation within 4 weeks of randomisation
l women who were pregnant, breastfeeding or who were planning to become pregnant.
Interventions
Asthma self-management plans
The asthma self-management plans used in the trial were based on the plan that was available from Asthma
UK9 and were widely used at the time of the trial’s design and protocol development. All participants were
randomised to either the usual-care or modified self-management plans, which differed only in instruction
at zone 2, which in the modified plan recommended a quadrupling of inhaled corticosteroid dose.
Zone 1 described the participant with well-controlled asthma and simply recommended that they continue
their usual treatment. Zone 3 described the development of an exacerbation and when to start systemic
corticosteroids and seek medical intervention and zone 4 described what to do with life-threatening
exacerbations. Both plans had the same wording so that participants in each group should, on average,
have started systemic corticosteroids at the same threshold.
Zone 2 included the current area of uncertainty and the research question under investigation.
Usual self-management plan
Participants in the usual-care group who reached zone 2 were instructed to use additional bronchodilator
medication to relieve asthma symptoms, as outlined in their individual asthma self-management plan.
Modified self-management plan
Participants in the modified self-management group who reached zone 2 were instructed to use additional
bronchodilator medication to relieve asthma symptoms and to increase their inhaled corticosteroid treatment
fourfold, either by increasing the number of puffs of their current inhaler, if they used a corticosteroid inhaler
(refer to Table 2), or by adding a corticosteroid inhaler to their treatment if they used a combination inhaler
(Table 3), as outlined in their individual asthma self-management plan. Those participants on combination
inhalers were not asked to simply increase the number of puffs because this would have led to an increase in
long-acting beta-agonist dose as well as the corticosteroid dose.
METHODS
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TABLE 2 How to achieve a quadrupling dose for participants on an inhaled corticosteroid-only inhaler
(i.e. beclometasone dipropionate, budesonide, fluticasone propionate and ciclesonide)
Current number of puffs per dose Number of puffs per dose to achieve quadrupled dose
1 o.d. 4 o.d.
2 o.d. 8 o.d.
1 b.i.d. 4 b.i.d.
2 b.i.d. 8 b.i.d.
And so on And so on
b.i.d., bis in die (twice a day); o.d., once daily.
TABLE 3 How to achieve a quadrupling dose for participants on a combination inhaler
Current treatment
Additional treatment options
Option 1 Option 2
Seretide® MDI 50/25 (GlaxoSmithKline,
Uxbridge, UK), 2 puffs b.i.d.
FP 50, 6 puffs b.i.d. FP 125, 3 puffs b.i.d.
Seretide MDI 125/25, 2 puffs b.i.d. FP 125, 6 puffs b.i.d. FP 250, 3 puffs b.i.d.
Seretide MDI 250/25, 2 puffs b.i.d. FP 250, 6 puffs b.i.d. N/A
Seretide Accuhaler® 100/50 (GlaxoSmithKline,
Uxbridge, UK), 1 puff b.i.d.
FP Disk 100, 3 puffs b.i.d. N/A
Seretide Accuhaler 250/50, 1 puff b.i.d. FP Disk 250, 3 puffs b.i.d. N/A
Seretide Accuhaler 500/50, 1 puff b.i.d. FP Diskhaler 500, 3 puffs b.i.d. N/A
Symbicort® Turbo® 100/6 (AstraZeneca UK Ltd,
Luton, UK), 1 puff b.i.d.
Bud Turbo 100, 3 puffs b.i.d. N/A
Symbicort Turbo 100/6, 2 puffs b.i.d. Bud Turbo 100, 6 puffs b.i.d. Bud Turbo 200, 3 puffs b.i.d.
Symbicort Turbo 200/6, 1 puff b.i.d. Bud Turbo 200, 3 puffs b.i.d. N/A
Symbicort Turbo 200/6, 2 puffs b.i.d. Bud Turbo 200, 6 puffs b.i.d. Bud Turbo 400, 3 puffs b.i.d.
Symbicort Turbo 200/6, 4 puffs b.i.d. Bud Turbo 400, 6 puffs b.i.d. N/A
Symbicort Turbo 400/12, 1 puff b.i.d. Bud Turbo 400, 3 puffs b.i.d. N/A
Symbicort Turbo 400/12, 2 puffs b.i.d. Bud Turbo 400, 6 puffs b.i.d. N/A
Fostair MDI 100/6 (Chiesi Ltd, Manchester, UK),
1 puff b.i.d.
Qvar MDI 100, 3 puffs b.i.d. N/A
Fostair MDI 100/6, 2 puffs b.i.d. Qvar MDI 100, 6 puffs b.i.d. N/A
Flutiform® MDI 50/5 (Napp Pharmaceuticals Ltd,
Cambridge, UK), 2 puffs b.i.d.
FP MDI 50, 6 puffs b.i.d. N/A
Flutiform MDI 125/5, 2 puffs b.i.d. FP MDI 125, 6 puffs b.i.d. FP MDI 250, 3 puffs b.i.d.
Flutiform MDI 250/10, 2 puffs b.i.d. FP MDI 250, 6 puffs b.i.d. N/A
b.i.d., bis in die (twice a day); Bud, budesonide; FP, fluticasone propionate; MDI, metered dose inhaler; N/A, not applicable;
o.d., once daily.
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It was perceived at the outset of the trial that all participants enrolled in the trial would benefit, as their
self-management plan would be explained to them in detail and monthly texts would be sent to prompt
them to adhere to it (if participants consented to this). It was believed that this would increase the
participant’s awareness of their asthma symptoms and allow them to implement their self-management
plan more reliably.
During the baseline visit, a member of the research team randomised each participant to their self-management
plan and talked through the allocated plan with the participant to ensure that they fully understood the
guidance at each zone. Those participants who were randomised to usual self-management were instructed
to ‘use your reliever inhaler to relieve your symptoms and continue your preventer medication at your normal
dose’. Those participants randomised to the modified self-management plan were instructed to ‘use your
reliever inhaler to relieve your symptoms and increase your preventer medication as described below’ and then
implement the zone 2 dose instructions in the self-management plan according to either:
l option 1: how to achieve a quadrupling dose for participants on an inhaled corticosteroid-only inhaler
l option 2: how to achieve a quadrupling dose for participants on a combination inhaler.
Outcome measures
Primary outcome
The primary outcome of ‘time to first asthma exacerbation’ was defined as the need for systemic
corticosteroids (for at least 3 consecutive days) and/or unscheduled health-care consultations for asthma
(i.e. reaching zone 3 or 4 of the Asthma UK self-management plan).
Secondary outcomes
l Number of participants who had an acute exacerbation of asthma.
l Total number of exacerbations.
l Number of participants using systemic corticosteroids for an acute exacerbation of asthma.
l Number of participants requiring unscheduled health-care consultations for asthma.
l Total number of courses of systemic corticosteroids for an acute exacerbation of asthma.
l Total number of unscheduled health-care consultations for asthma.
l Time to participants requiring systemic corticosteroids for an acute exacerbation of asthma.
l Time to unscheduled health-care consultations for asthma.
l Area under the morning peak flow curve over 2 weeks from the point of activating zone 2 of the
asthma plan.
l Change in Mini AQLQ score 2 weeks after activating zone 2 of the self-management plan.
l Cumulative dose of inhaled and systemic corticosteroids used in the 12 months after randomisation.
l Cost and resource audits of both trial arms, reported as incremental cost per asthma exacerbation
prevented and cost per quality-adjusted life-year (QALY) gained.
Safety outcomes
Known side effects of inhaled corticosteroids were collected because of the quadrupling of the dose of
inhaled corticosteroid in the modified self-management group.
Data collection
Trial data generated by all centres were entered by site staff directly into a web-based bespoke database,
designed and maintained by the Nottingham Clinical Trials Unit (NCTU). Access to the trial database was
controlled by user logins, and users could enter or edit data only for their regional centre. Participant
questionnaires, completed at clinic visits, were entered into the trial database by site staff. If participants
METHODS
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had not activated zone 2 of their self-management plan and were unable to attend the 6- and/or 12-month
visit in person, site staff contacted participants via telephone and completed the trial database directly with
the information provided to them over the telephone. Any missing and/or ambiguous data were queried
with site staff, by the NCTU team, and resolved wherever possible.
Participants were asked to complete their diary cards prior to attending their post-activation visit. This diary
card is where the participants recorded peak flow and the asthma medication used to manage symptoms
(including the number of puffs of usual preventer inhaler, extra corticosteroid inhaler, reliever inhaler and
whether or not any systemic corticosteroids were taken) and documented whether they had an asthma-
related GP or hospital appointment. The diary was reviewed by the site staff at each clinic appointment
and this information was used to complete the relevant sections of the trial database.
Site staff were also required to assess the participant’s adherence to the asthma self-management plan by
reviewing the diary card and discussing, during the visit, whether or not, and how, participants changed their
inhaled treatment since activating zone 2 of their self-management plan. Site staff completed the adherence
assessment directly into the web-based bespoke system. Initially, there was the option for the first 200
participants recruited to measure their actuation adherence with the smart inhaler. The participant’s
corticosteroid inhaler would be fitted with the electronic dose counter to record the date and time of each
actuation. The data would then be directly downloaded from the device during the participant’s visit and
uploaded to a separate database. The smart inhaler devices were not implemented because of the challenges
described in Trial design and all adherence data were assessed by the site staff.
The web-based bespoke system generated automated notification e-mails for sites to remind them of
upcoming and overdue 6- and 12-month visits. These notification e-mails were sent to sites on a monthly
basis on the first day of every month during the recruitment and follow-up phase of the trial.
Those participants who provided additional consent, were sent monthly text reminders to remind them to
adhere to their asthma self-management plan. The text message service was automated, with text messages
automatically initiated on the first day of every month at approximately noon. To maintain confidentiality
the participant’s mobile phone number was entered on to the database by site staff at the point of consent.
These data were then encrypted and stored confidentially. Only research staff at their own specific site had
access to their participants’ mobile phone numbers. If the participant withdrew, was lost to follow-up or
had completed the trial, then the text messages automatically stopped being sent to the participant.
Informed consent
Written informed consent was obtained for all participants prior to any trial procedures being undertaken.
Consent to receive a summary of the results of the study and for the research team to send monthly
reminder text messages to the participant was included as optional.
Sample size
A reduction of one-third in the number of people requiring treatment with oral corticosteroids was
considered an important treatment effect by a group of local GPs, asthma nurses and asthma experts.
With 1000 participants per group, a log-rank test (at the two-sided 5% significance level) provided at least
90% power to detect a difference of 30% (relative effect), assuming an exacerbation rate of 13% in the
control group. A 13% exacerbation rate requiring systemic corticosteroids was the lowest level seen in the
control group of previous studies of this type6,10 and so provided a conservative estimate. The study initially
proposed to recruit 2300 participants to allow for participants lost to follow-up (i.e. approximately 15%
lost to follow-up). The study was not powered for the subgroup analysis performed on smoking status or
dose of maintenance inhaled steroid dose at baseline.
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The power calculation was revised in March 2015 in consultation with the NIHR HTA programme. The overall
event rate in the first 226 participants recruited was higher (around 50%) in those reaching the 12-month
follow-up time point. The exacerbation rate at this time was thought to be high because of more participants
being recruited from secondary care and, therefore, having more severe asthma; hence, a lower exacerbation
rate was used to revise the sample size calculation. Assuming an exacerbation rate in the control group of 17%
and 90% power, and still estimating a one-third reduction in the fourfold increase group, then a sample size of
1542 participants was needed for analyses. Allowing for 20% of participants being lost to follow-up, the study
aimed to recruit between 1774 and 1850 participants before the close of recruitment on 31 January 2016.
For those participants who were lost to follow-up, where possible, site staff reviewed participant computerised
medical records to document if they had had an asthma-related GP appointment, if their asthma had
exacerbated or if they had been prescribed systemic steroids.
Stopping rules and discontinuation
Ongoing adherence to the self-management plans was assessed by the Data Monitoring Committee in
accordance with the criteria outlined in Table 4.
Randomisation
Randomisation was stratified by regional centre (Box 1), smoking status (yes/no) and maintenance inhaled
corticosteroid dose (high/low dose; Table 5). Participants were allocated with equal probability to the two
trial treatment groups. Recruiting sites were grouped into regional centres, which grouped practices to the
appropriate CRN regions or secondary hospital care sites (Box 1). The treatment group to which a participant
was assigned was determined by a computer-generated pseudo-random code, with random permuted
blocks of randomly varying size, that was created by the NCTU in accordance with its standard operating
procedure. The data were held on a secure University of Nottingham server.
Research nurses accessed the randomisation website by means of a remote, internet-based randomisation
system developed, and maintained, by NCTU. Access was controlled by unique user logins. The sequence
of treatment allocations was concealed until interventions had all been assigned and recruitment and data
collection were complete. The chief investigator, trial team and trial statisticians were blinded to treatment
allocations until the database was locked.
TABLE 4 Stop criteria
Level of adherence in both groups Proposed action
≥ 50% of participants with moderate or good adherence
with self-management compliance
Continue with trial as planned
≤ 49% –≥ 30% of participants with moderate or
good adherence with self-management compliance
Implement pragmatic strategies for improvement
≤ 29% of participants with moderate or good adherence
with self-management compliance
Stop trial unless rectifiable solution can be
readily implemented
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
BOX 1 Site
l Aberdeen Royal Infirmary.
l Aintree University Hospital.
l Arrowe Park Hospital.
l Blackpool Victoria Hospital.
l Bradford Royal Infirmary.
l East of England.
l Freeman Hospital, Newcastle.
l Hetton Group Practice.
l Kent.
l King’s Mill Hospital.
l Leicester Glenfield Hospital.
l Nottingham City Hospital.
l Royal Liverpool and Broadgreen University Hospitals.
l Southampton.
l South West Peninsula.
l Surrey and Sussex.
l Thames Valley and South Midlands.
l West Midlands (South).
l West of England.
l Wythenshawe Hospital, Manchester.
TABLE 5 High and low corticosteroid doses for stratification purposes
Steroid Device and formulation
Dose (mcg/day)
Low High
BDP Non-proprietary 100–1000 > 1000–2000
BDP Clenil® (Chiesi Ltd, Manchester, UK) MDI 100–1000 > 1000–2000
BDP Qvar MDI 50–500 > 500–800
Budesonide MDI 100–1000 > 1000–1600
Budesonide Turbuhaler 100–800 > 800–1600
Fluticasone propionate MDI/Accuhaler 50–500 > 500–2000
Ciclesonide MDI 80–320
Seretide MDI/Accuhaler 50–500 > 500–1000
Symbicort Turbuhaler 100–800 > 800–1600
Fostair MDI 400
Flutiform MDI 50–500 > 500–1000
BDP, beclometasone dipropionate; MDI, metered dose inhaler.
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Blinding
Owing to the nature of the self-management plans allocated in the trial, it was not possible to blind site
staff or participants to their treatment allocation. Efforts were made to minimise the expectation bias
by detailing in the trial documents that the evidence supporting the quadrupling of the inhaled dose of
corticosteroid at the time of worsening asthma symptoms was limited, and it was not yet known whether
or not the intervention offered any benefit over usual care. Both groups were also provided with tailored
self-management plans that were explained to them in detail, ensuring that both groups received similar
instruction on how to best use their asthma self-management plan.
Throughout the trial, prior to database lock, the blinding allocation was preserved for the chief Investigator,
trial statisticians, the trial team and TSC members.
Full details of blinding arrangements are summarised in Table 6.
Statistical analysis
Analyses are detailed in the statistical analysis plan (www.nottingham.ac.uk/nctu/trials/respiratory.
aspx#FAST), which was finalised prior to database lock and release of the treatment allocation codes
for analysis.
All analyses were based on the intention-to-treat principle, for example analysed as randomised regardless
of adherence to self-management plan. All analyses were carried out using Stata®/SE 13.1 (StataCorp LP,
College Station, TX, USA).
Preliminary analyses
Descriptive statistics of demographic and clinical measures were used to examine balance between the
randomised groups at baseline.
Descriptive analyses
The number of participants activating zone 2 or above of the self-management plan was derived from
the following information on the electronic Case Report Form (eCRF): summary pages for diary cards,
post-activation visit pages, summary pages for oral corticosteroid use for asthma, summary pages for
health-care consultations for asthma and a question about unreported activations at the scheduled visits.
Therefore, the source of the date of the first activation, diary card completion and post-activation visit
attendance for the first activation to zone 2 is tabulated by allocated group. The research nurse rating of
adherence is described with frequencies and percentages for the first activation to zone 2. Adherence
information is unknown for participants who did not report their activation to zone 2 or complete their
diary card.
TABLE 6 Summary of blinding arrangements
Role within trial Blinding status Comments
Participants Not blinded Not possible to blind participants, efforts made to minimise expectation bias
Research nurses and
principal investigators
Not blinded Acted as the main point of contact for participants. Not possible to blind
research staff, efforts made to minimise bias
Trial staff at NCTU Blinded Acted as the main point of contact for recruiting centres. All trial
documentation finalised prior to revealing treatment codes
Statisticians Blinded Statisticians finalised the statistical analysis plan prior to revealing the
treatment codes
Chief investigator Blinded Finalised all documentation prior to revealing treatment codes
METHODS
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Asthma exacerbation outcomes
An asthma exacerbation was defined as the need for a course of systemic corticosteroids and/or an unscheduled
health-care consultation for asthma. A course of systemic corticosteroids was defined as taking 3 consecutive
days or more of corticosteroids. Health-care consultations and courses of systemic corticosteroids were counted
as part of the same exacerbation if they were within 14 days of the previous health-care consultation or course
of systemic corticosteroids for asthma.
Similarly, for the derivation of the total number of courses of systemic corticosteroids, corticosteroids started
within 14 days of the last date of the previous course of corticosteroids were counted as within the same
course. For the derivation of the total number of unscheduled health-care consultations, GP/hospital visits
were classed as one unscheduled health-care visit if they were within 14 days of the previous visit.
The analysis population for the asthma exacerbation outcomes (including systemic corticosteroids and
unscheduled health visits) was all participants apart from those with whom there was no further contact
after randomisation and, therefore, information was unavailable about oral steroid use or unscheduled
health-care consultations for asthma (i.e. questions on eCRF answered as unknown or not answered).
Attendance at a scheduled or post-activation visit or a completed diary card was considered as contact
after randomisation.
The questions about oral corticosteroid use or unscheduled health-care consultations for asthma on the
eCRF were not expected to be answered as unknown, as the protocol specified that health-care records
could be checked for participants who did not complete the 12-month follow-up visit but who did not
withdraw consent. Some sites, however, did not have access to health-care records if the participant had
moved surgery or if the participant was recruited from a secondary care site. In these circumstances,
the questions could be answered as unknown.
Primary outcome: time to first asthma exacerbation
For the analysis of time to first asthma exacerbation, the start time was the date of randomisation and the
end time was either:
l the date of first starting to take systemic corticosteroids (provided these were taken for at least
3 consecutive days) or the date of the first unscheduled health-care consultation for asthma
(if within 365 nights after randomisation) (whichever happened first)
l censored for participants who did not take systemic corticosteroids for more than 3 consecutive days or
have an unscheduled health-care consultation (or if this occurred more than 365 days after randomisation)
at the:
¢ 12-month follow-up date for participants who completed the trial (or 365 days if the 12-month
follow-up date was after this)
¢ date of withdrawal for participants who withdrew consent
¢ date of death for participants who died
¢ date of last contact in the case of participants who moved to another GP practice during the trial
¢ scheduled 12-month follow-up date (i.e. 365 days after randomisation) for all other participants who
did not complete the trial as a result of being lost to follow-up or other reasons (sites were asked to
check GP records for these participants to ascertain the primary outcome over the trial period).
l censored for participants where it was unknown if they took any systemic corticosteroids or had an
unscheduled health-care consultations at the:
¢ last date the participant was known to be in the trial, that is, whichever was last of the latest dates
from the diary [provided peak expiratory flow (PEF) data or some information on the number of
puffs on inhalers was recorded], post-activation visit date or 6-month visit date
¢ randomisation date for all other scenarios.
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The number of participants with an asthma exacerbation, the total number of person-years to first
exacerbation and the rate for first asthma exacerbation are summarised by allocated group. The time to
first asthma exacerbation is presented in Kaplan–Meier plots, with a table showing the number at risk.
The hazard ratio for an asthma exacerbation in the modified self-management group compared with the
usual-care group was calculated using Cox proportional hazards regression (using the Breslow method
for tied failure times), including the randomisation stratification variables dose of inhaled corticosteroid
(high/low) and smoking status (never, former, current) as covariates and using a shared frailty model to
account for stratification by regional centre.11 In addition, the unadjusted hazard ratio is reported.
The proportional hazards assumption was tested by using a log–log plot of survival and using Schoenfeld’s
residuals.
Sensitivity analyses for the primary outcome
The hazard ratio for time to asthma exacerbation was further adjusted for age, sex and peak flow at
screening. These were chosen based on previous literature as being strong predictors of asthma
exacerbation.
Prespecified subgroup analyses for the time to first asthma exacerbation for smoking status at trial entry
(never, former, current) and dose of inhaled corticosteroid at trial entry (high/low) were conducted by
including an interaction term with allocated group in the Cox proportional hazards regression model,
adjusting for randomisation stratification variables.
The main analysis of the primary outcome specified above was repeated for the per-protocol population.
The per-protocol population was defined as participants who activated zone 2 and had good adherence to
their self-management plan during their first activation, as assessed by the research nurse, and participants
who completed the study as planned (i.e. attended the 12-month follow-up) and did not activate zone 2.
Note that this is a non-randomised comparison and, therefore, should be interpreted with caution.
Exploratory analyses were also performed to examine the robustness of the conclusions from the main
analysis to the date of censoring for the participants who did not complete the 12-month visit.
Secondary outcomes
For secondary outcomes, the same approach for analyses was taken as for the primary outcome. The results
are summarised by allocated group and the analysis models (used to estimate the intervention effect) included
the randomisation stratification variables of corticosteroid dose, smoking status and regional centre as
covariates.
Secondary exacerbation outcomes
The time to participants requiring a course of systemic corticosteroids and time to participants requiring an
unscheduled health-care consultation were analysed using the methods described above for the primary
outcome.
The difference in the percentage of participants with an asthma exacerbation requiring a course of
corticosteroids and requiring an unscheduled health-care consultation was compared between the two
allocated groups using generalised estimating equations with the binomial family and:
l an identity link to estimate the risk differences
l a log-link to estimate the risk ratios.
An exchangeable correlation matrix was used to account for randomisation being stratified by regional centre.
METHODS
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The total number of asthma exacerbations per participant, the total number of courses of systemic
corticosteroids and the total number of unscheduled health-care consultations per participant were
summarised in the two allocated groups and compared with a negative binomial model using generalised
estimating equations to account for randomisation being stratified by regional centre. The number of
days in the trial was used as time at risk in the negative binomial model. Incidence rate ratios with 95%
confidence intervals (CIs) are presented.
Area under the morning peak flow curve over 2 weeks from the point of activating
zone 2 of the asthma plan
The area under the peak flow curve was specified as a secondary outcome to explore whether or not the
severity of the deterioration in asthma control differed between the allocated groups. After zone 2 activation,
peak flow data were to be collected on the diary cards for 14 days.
The percentage baseline peak flow was used for analysis and was calculated as actual PEF × 100/(screening
visit PEF). The area under the curve for each participant was calculated in Stata using the cubic spline method.12
Participants with a diary card completed for the first activation to zone 2 and with a PEF measurement on
day 1, at least one PEF measurement on or after day 10 and at least one PEF measurement in between
day 1 and 10 were included in the analysis. The area under the curve was calculated for the two analysis
populations:
1. participants with a PEF measurement on day 1, at least one PEF measurement on or after day 10 and
at least one PEF measurement in between days 1 and 10
2. participants with a PEF value recorded on day 1 and day 14 and at least six PEF values between days 1
and 14.
For both of the analyses above on days when PEF was not recorded in the diary, the PEF value was imputed
using the last PEF value recorded.
Linear regression with a random effect for regional centre was used to compare the area under the
percentage baseline morning peak flow curve. Baseline PEF was also included as a covariate (along with
the randomisation stratification variables), as this was felt likely to be prognostic for PEF values during
activation to zone 2.
Change in the Mini Asthma Quality of Life Questionnaire score 2 weeks after activating
zone 2 of the self-management plan
The Mini AQLQ measures the functional problems (symptoms, activities, emotions and environment) that
are most troublesome to adults with asthma. It has 15 items each with seven response options (where 1
indicates severely impaired and 7 indicates not at all impaired) and a recall period of 2 weeks. The Mini
AQLQ score was calculated from the mean of all 15 responses. The mean score for participants with
missing items was calculated if no more than two items were missed. If more than two items were missed,
the Mini AQLQ score was not calculated.
Participants with a Mini AQLQ for the first activation to zone 2 completed within 28 days of the start of
the activation (because of the time window for the post-activation visit in relation to activation of zone 2)
were included in the analysis of change in the Mini AQLQ. Mini AQLQ questionnaires completed more
than 28 days after first activating zone 2 were not included.
The overall Mini AQLQ score is summarised at baseline and 2 weeks after activating zone 2 or above.
In addition, the score was compared between allocated groups using a linear regression model adjusting
for the Mini AQLQ score at baseline [i.e. analysis of covariance (ANCOVA)] and randomisation stratification
variables with a random effect for regional centre.
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If the Mini AQLQ score was missing at baseline, for inclusion in the regression analysis the score was
imputed using the mean baseline score at the participant’s regional centre.13
Cumulative dose of inhaled and systemic steroids used in the 12 months
after randomisation
Participants attending and completing the 12-month follow-up visit were included in the analysis of cumulative
dose of inhaled and systemic steroids.
The cumulative dose of inhaled corticosteroids was derived from the information collected at visits (scheduled
and post activation) about permanent asthma medication, including changes in medication, and from the
information entered from the diary cards about inhaler use during activation to zone 2 or above. Participants
were assumed to have taken their normal number of puffs on their preventer inhaler for days when no
information was recorded on the diary card.
The cumulative doses of inhaled corticosteroids and systemic corticosteroids taken per participant over the
365 days from randomisation are summarised descriptively by allocated group. The cumulative dose of
systemic corticosteroids taken is summarised for all participants and includes only participants who took
systemic corticosteroids.
Safety
Adverse events were reported during the 14 days following activation of zone 2 of the self-management plan;
therefore, safety data are summarised for participants activating zone 2 or above of their self-management
plan on at least one occasion.
The number and percentage of participants experiencing a serious adverse event (SAE), seriousness criteria,
total number of SAEs, SAE description [using the Medical Dictionary for Regulatory Activities (MedDRA)14
terminology-preferred term] and classification (not related to trial treatment, related to trial treatment –
not unexpected) are summarised by allocated group.
The number and percentage of participants experiencing a non-serious AE, total number of non-serious
AEs, AE description (using the MedDRA-preferred term) and relationship to inhaled steroids are summarised
by allocated group. Non-serious AEs reported that were not considered to be known side effects of inhaled
corticosteroids (e.g. displaced fractures) are not included in the summaries.
Summary of changes to the protocol
The full protocol and statistical analysis plan are available on the NCTU’s website (www.nottingham.ac.uk/
nctu/trials/respiratory.aspx#FAST). A summary of changes made to the protocol after the start of recruitment
is listed in Appendix 2.
METHODS
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Chapter 3 Results
Recruitment
Recruitment to the trial took place between 17 May 2013 and 29 January 2016 (Figure 2).
During this time 20,695 asthma patients were contacted and invited to take part in the study (patient
contact data were not provided by 77 of the initiated sites). Of these, 4811 were assessed for eligibility
and 1922 were subsequently randomised (Figure 3). Of the 2889 participants who were screened but
not randomised, 860 (30%) declined to participate and 2029 (70%) failed to meet the eligibility criteria
(Table 7).
Initially, recruitment was slow, and after 6 months was only 25% of the target as a result of a combination of
delays with contracting and a higher than expected rate of non-eligibility. Following review of site recruitment
and recruitment trends in primary and secondary care, focus was shifted to concentrate on primary care RISs.
Although the RISs were initially achieving target after around 6 months, the pool of potential participants was
exhausted and recruitment dropped. In February 2014, FAST’s Trial Management Group met the trial funders
to agree on a strategy that new RISs should be opened to replace sites as they became inactive. Following the
meeting, an ambitious initiation plan was undertaken, with 54 sites opening between March and December
2014 and a further 107 sites opening in 2015.
In order to meet recruitment targets the NIHR HTA programme agreed to an 11-month recruitment
extension (January 2015). The trial completed recruitment on 31 January 2016 with 1922 randomised
participants and 196 RISs and 11 secondary care sites initiated throughout the recruitment period. At the
outset of the study it was envisaged that approximately 80% of participants would be recruited from
primary care (i.e. PICs). In total, 81% of participants were recruited from primary care (63% RISs and 18%
PICs) and 19% from secondary care sites. The number of participants randomised to each group was well
balanced across regional randomisation centres (Table 8).
Baseline data
Participants
The characteristics of the participants at baseline were well balanced between the usual-care and modified
self-management groups (Table 9).
The mean age of participants was 57 years [standard deviation (SD) 15 years] and 1305 (68%) were female.
Of those enrolled, 1344 (70%) were prescribed combination inhalers, and 1495 (78%), the majority of
participants, were on a low dose of maintenance steroid [≤ 1000 mcg/day of beclometasone dipropionate
(BDP)]. Overall, 1125 participants (59%) reported not taking any other respiratory medication at
randomisation (Table 10).
Follow-up
Scheduled follow-up visits
Attendance by participants at the scheduled visits was good. In the usual-care group, 772 (80%) participants
attended the 6-month visit, decreasing to 700 (73%) at the 12-month visit. Attendance was similar in the
modified self-management group, with 773 (81%) participants attending the 6-month visit and 679 (71%)
attending the 12-month visit.
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Invited
(n = 20,695)a
Assessed for eligibility
(n = 4811)
Randomised
(n = 1922)
Allocated to usual-care group
(n = 965)
Allocated to modified group
(n = 957)
At least one activation of zone 2 or above of the
self-management plan
(n = 552)
Excluded
(n = 2889)
• Not meeting eligibility criteria, 
   n = 2029
• Declined to participate, 
   n = 860
• Did not report increasing inhaled
   corticosteroid treatment, n = 233
• Reported increasing inhaled corticosteroid
   treatment, n = 102
• Did not report, n = 217
At least one activation of zone 2 or above of the
self-management plan
(n = 562)
Included in analysis of primary outcome
(n = 938)
Included in analysis of primary outcome
(n = 933)
Not included in analysis of primary outcome
(n = 27)
Not included in analysis of primary outcome
(n = 24)
• Exacerbation started on same day as 
   randomisation, n = 1
• Withdrew consent on same day as 
   randomisation, n = 1
• No follow-up information on asthma
   exacerbations available, n = 25
• Exacerbation started on same day as 
   randomisation, n = 2
• Withdrew consent on same day as 
   randomisation, n = 1
• No follow-up information on asthma
   exacerbations available, n = 21
• Reported increasing inhaled corticosteroid
   treatment fourfold, n = 282
• Did not report increasing inhaled
   corticosteroid treatment fourfold, n = 120
• Did not report, n = 160
FIGURE 3 The Consolidated Standards of Reporting Trials (CONSORT) participant flow diagram. a, Invited figure
reflective of the data provided by 132 initiated sites at the time of reporting.
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TABLE 7 Expanded exclusion criteria
Reason for not meeting eligibility criteria Number of participants
No systemic corticosteroids in the past year 594
On maintenance corticosteroids 340
Exacerbated in the last 4 weeks 47
SMART regimen 365
COPD 577
Other 106
Pregnant/breastfeeding 20
Mental/learning difficulties 39
Unlicensed dose of inhaled steroid 11
On Relvar® Ellipta (GlaxoSmithKline UK Ltd, Brentford, UK) 5
No reason given 31
SMART, Single inhaler Maintenance and Reliever Therapy.
TABLE 8 Trial recruitment by intervention arm and regional randomisation centre number
Region
Intervention arm, n (% of total)
Total (N= 1922), n (% of total)Usual care (N= 965) Modified (N= 957)
1 133 (14) 132 (14) 265 (14)
2 45 (5) 45 (5) 90 (5)
3 31 (3) 31 (3) 62 (3)
4 9 (1) 9 (1) 18 (1)
5 77 (8) 76 (8) 153 (8)
6 92 (10) 93 (10) 185 (10)
7 99 (10) 100 (10) 199 (10)
8 179 (19) 176 (18) 355 (18)
9 22 (2) 23 (2) 45 (2)
10 8 (1) 8 (1) 16 (1)
11 5 (1) 6 (1) 11 (1)
12a 5 (1) 5 (1) 10 (1)
13 38 (4) 35 (4) 73 (4)
14 25 (3) 25 (3) 50 (3)
15 103 (11) 104 (11) 207 (11)
16 13 (1) 13 (1) 26 (1)
17 and 18 12 (1) 10 (1) 22 (1)
19 37 (4) 35 (4) 72 (4)
20 29 (3) 28 (3) 57 (3)
21 3 (< 0.5) 3 (< 0.5) 6 (< 0.5)
a Practice in region 12 was incorrectly set up as an individual randomisation centre.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
TABLE 9 Baseline characteristics
Characteristic
Intervention arm
Total (N= 1922)Usual care (N= 965) Modified (N= 957)
Age (years)
Mean (SD) 56.7 (15.2) 56.2 (15.5) 56.5 (15.3)
Min., max. 19, 94 16, 91 16, 94
Sex, n (% of total)
Male 316 (33) 301 (31) 617 (32)
Female 649 (67) 656 (69) 1305 (68)
Recruited from, n (% of total)
Primary care 774 (80) 785 (82) 1559 (81)
Secondary care 191 (20) 172 (18) 363 (19)
PEF (l/minute) at screening
Mean (SD) 381.1 (112.2) 386.9 (110.8) 384 (111.5)
Type of inhaler, n (% of total)
Corticosteroid 303 (31) 275 (29) 578 (30)
Combination 662 (69) 682 (71) 1344 (70)
Maintenance dose of inhaled corticosteroids (mcg/day of BDP)
Median (25th, 75th centiles) 800 (400, 1000) 800 (400, 1000) 800 (400, 1000)
Min., max. 100, 4000 80, 4000 80, 4000
Maintenance dose of inhaled corticosteroids (used in randomisation stratification), n (% of total)
Low (≤ 1000 mcg/day of BDP) 752 (78) 743 (78) 1495 (78)
High (> 1000 mcg/day of BDP) 213 (22) 214 (22) 427 (22)
BTS step of asthma treatment, n (% of total)
Step 2 – regular preventer therapy 259 (27) 221 (23) 480 (25)
Step 3 – initial add-on therapy 363 (38) 345 (36) 708 (37)
Step 4 – persistent poor control 330 (34) 374 (39) 704 (37)
Step 5 – omalizumab 3 (0.3) 2 (0.2) 5 (0.3)
Not knowna 10 (1) 15 (2) 25 (1)
Smoking status, n (% of total)
Never 552 (57) 564 (59%) 1116 (58)
Current 66 (7) 59 (6) 125 (7)
Former 347 (36) 334 (35) 681 (35)
continued
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TABLE 9 Baseline characteristics (continued )
Characteristic
Intervention arm
Total (N= 1922)Usual care (N= 965) Modified (N= 957)
Pack-years for current or former smokers
n 413 393 806
Mean (SD) 13.9 (16.1) 12.3 (14.5) 13.1 (15.4)
Mini AQLQ overall scoreb
n 959 944 1903
Mean (SD) 5 (1.2) 5.1 (1.2) 5.1 (1.2)
BDP, beclometasone dipropionate; max., maximum; min., minimum.
a The BTS step was unknown for participants on low-dose steroid inhalers (i.e. ≤ 1000 mcg/day of BDP) and not known if
other respiratory medications were being taken at randomisation.
b The Mini AQLQ scores range from 1 to 7, higher scores indicating better QoL. The Mini AQLQ scores are not known for
19 participants (six in the usual-care group and 13 in the modified self-management group): one participant who missed
three items, one participant who missed five items, 16 participants who did not complete the questionnaire and one
participant for whom no information was entered on the database.
Note
The BTA steps were based on the 2014 guidelines.
TABLE 10 Other respiratory medications being taken at randomisation
Medication
Intervention arm, n (% of total)
Total (N= 1922),
n (% of total)Usual care (N= 965) Modified (N= 957)
None 572 (59) 553 (58) 1125 (59)
At least one medication reported 360 (37) 363 (38) 723 (38)
Unknown 33 (3) 41 (4) 74 (4)
Preventer medication
Theophylline/aminophylline 16 (2) 21 (2) 37 (2)
Sodium cromoglycate – 1 (< 0.5) 1 (< 0.5)
Omalizumab 3 (< 0.5) 2 (< 0.5) 5 (< 0.5)
Reliever medication
Long-acting beta agonist 12 (1) 14 (1) 26 (1)
Long-acting muscarinic antagonist 38 (4) 39 (4) 77 (4)
Leukotriene antagonist 81 (8) 94 (10) 175 (9)
Nebulised beta agonist 3 (< 0.5) 1 (< 0.5) 4 (< 0.5)
Nebulised anticholinergic 7 (1) 8 (1) 15 (1)
Short-acting beta agonist (not nebulised) 311 (32) 312 (33) 623 (32)
Other respiratory medication
Antibiotics 6 (1) 5 (1) 11 (1)
Oral/inhaled corticosteroids 99 (10) 112 (12) 211 (11)
Other 42 (4) 47 (5) 89 (5)
Notes
Not mutually exclusive; participants may have been taking more than one type of other respiratory medications
at randomisation.
The oral/inhaled steroid category includes asthma preventer inhalers (inhaled steroid/combination inhaler).
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A total of 67 (7%) participants in the usual-care group and 80 (8%) in the modified self-management group
withdrew consent from the trial, 15% of participants were lost to follow-up and 5% of participants in each
group were marked as not completing the trial for other reasons (Table 11). The other reasons reported for
participants not attending the 12-month visit included moving area or GP surgery, being advised to switch
to a Single inhaler Maintenance And Reliever Therapy (SMART) regimen, and a variation or stopping in
inhaled steroid dose.
Activation to zone 2 or above of the self-management plan
A total of 1114 participants (58%) activated zone 2 or above of the self-management plan in the year
after randomisation, with similar numbers in the two groups (552 in the usual-care group and 562 in the
modified self-management group). The baseline characteristics of the participants who activated zone 2
or above were similar in the two groups (Appendix 6). However, a greater percentage of participants
completed a diary card and attended the post-activation visit for the first activation of zone 2 in the
modified self-management group than in the usual-care group (Table 12).
TABLE 11 Attendance at final scheduled follow-up visit at 12 months
Attendance
Intervention arm, n (% of total)
Usual care (N= 965) Modified (N= 957)
Attended 700 (73) 679 (71)
Did not attend 260 (27) 274 (29)
No information 5 (0.5) 4 (0.4)
Reason if did not attend 12-month visit
Lost to follow-up 147 (15) 145 (15)
Withdrawal of consent 67 (7) 80 (8)
Other 44 (5) 47 (5)
Deatha 1 (0.1) 1 (0.1)
No information 1 (0.1) 1 (0.1)
a Deaths were reportable as SAEs only if they occurred during the 14-day active treatment period (i.e. zone 2).
The participant who died in the usual-care group did not have an exacerbation of asthma prior to death.
TABLE 12 Activation to zone 2 or above of the self-management plan
Activation
Intervention arm, n (% of total)
Usual care (N= 552) Modified (N= 562)
Source of date of first activation
Diary card 328 (59) 400 (71)
Post-activation visit 2 (< 0.5) 3 (1)
Health-care consultation or oral corticosteroid use for asthma 203 (37) 137 (24)
Date not known (unreported activationa) 19 (3) 22 (4)
Post-activation visit attended for first activation to zone 2 or above 263 (48) 341 (61)
Diary card completed for first activation to zone 2 or aboveb 334 (61) 403 (72)
a Activations reported at the scheduled follow-up visits that were not reported at the time of the activation.
b Includes nine participants whose first activation to zone 2 was for an unscheduled health-care consultation or oral
steroid use for asthma, in which the diary was started within 1 week.
Note
At least one activation to zone 2 or above.
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Nurse-assessed adherence to the allocated intervention
Adherence to the allocated self-management plan was rated by research nurses using either information
entered in diaries or, if the diary was not completed, participant recall of this information at post-activation
visits. The ratings were based on the criteria specified in the protocol and are shown in Table 13.
Adherence to the self-management plan was assessed as good (i.e. fourfold increase in corticosteroid
dose as per instructions) for the first activation of zone 2 or above for 282 (50%) of the participants in
the modified self-management group (Table 14). In the usual-care group, adherence for 15 participants
(3%) was assessed as poor (i.e. used a fourfold increase in maintenance corticosteroid dose during first
activation to zone 2) (Table 14).
Adherence information was unknown for 377 participants: 331 participants, first activation to zone 2 or
above was an asthma exacerbation (health-care consultation or oral corticosteroid use for asthma; Table 12),
41 participants had an unreported activation and five participants had diary data but no nurse assessment
of adherence entered on to the database. Adherence information is unknown for a greater percentage of
participants who activated zone 2 or above in the usual-care group than in the modified self-management
group (39% and 28%, respectively) (Table 14), as the percentage of participants completing diary cards was
lower in the usual-care group.
Inclusion in the analysis of the primary outcome
There were 938 participants (97%) in the usual-care group and 933 participants (97%) in the modified
self-management group included in the primary analysis of the primary outcome (Table 15). Of these, 134
and 158 participants in the usual-care and modified self-management group, respectively, were censored
for the primary outcome as they did not have an exacerbation of asthma or complete the 12-month visit
(Table 15).
TABLE 14 Nurse-assessed adherence to the self-management plan during the first activation of zone 2 or above
based on participant-reported use of the inhaler
Adherence
Intervention arm, n (% of total)
Usual care
(N= 552) Modified (N= 562)
Poor 15 (3) 31 (6)
Moderate 87 (16) 89 (16)
Good 233 (42) 282 (50)
Not known 217 (39) 160 (28)
Note
Adherence data were used for nine participants whose first activation to zone 2 was an exacerbation, in which the diary
card was started within 6 days of the exacerbation.
TABLE 13 Criteria for adherence ratings from the protocol
Rating
Intervention arm
Usual care Modified
Poor Fourfold increase in maintenance dose No or minimal change in medication
Moderate Increase in maintenance dose,
but less than fourfold
Change, but as fourfold or as instructed
Good No change in inhaled corticosteroid dose Fourfold change and followed instructions
RESULTS
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No information was collected after randomisation for 26 participants (3%) in the usual-care group and
22 (2%) in the modified self-management group (Table 15). Therefore, these participants could not be
included in the analysis of the primary outcome.
Three participants had asthma exacerbations that started on the same day as randomisation. These
participants are not included in the analysis of the primary outcomes, but are included in other analyses
relating to exacerbations of asthma.
Primary and secondary outcomes
Primary outcome: time to first asthma exacerbation
Primary analysis
The number of participants having an exacerbation of asthma in the year after randomisation was
484 (51.6%) in the usual-care group and 420 (45.0%) in the modified self-management group (Figure 4).
Kaplan–Meier curves for the time to first asthma exacerbation are shown in Figure 4. The adjusted hazard
ratio for the time to first asthma exacerbation in the modified self-management group compared with the
usual-care group was 0.81 (95% CI 0.71 to 0.92; p = 0.002; Table 16).
TABLE 15 Follow-up for primary outcome of time to first asthma exacerbation
Primary outcome status
Intervention arm, n (% of total)
Usual care (N= 965) Modified (N= 957)
Unknown information about oral corticosteroid use or unscheduled
health-care consultations for asthma after randomisation – not included
in analysis of primary outcome
26 (3) 22 (2)
Participant had asthma exacerbation and/or completed the 12-month
follow-up visit
805 (83) 777 (81)
Exacerbation started on day of randomisation – not included in
analysis of primary outcomea
1 2
Participant did not have asthma exacerbation and did not complete the
12-month follow-up visit – censored for primary outcome
134 (14) 158 (17)
Censored at
Date of death 1 0
Date withdrew consent 32 34
Date left surgery 3 5
Scheduled 12-month visit date 91 107
6-month visit date 6 10
Post-activation visit date 1 2
a A participant in the usual-care group had an unscheduled health-care visit on the same day as randomisation. There
were two participants in the modified self-management group who had a course of oral steroids starting on the same
day as randomisation.
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Secondary analysis for the primary outcome
Additional adjustment
The hazard ratio for the time to first asthma exacerbation in the modified self-management group compared
with the usual-care group with additional adjustment for age, sex and PEF at screening was 0.80 (95% CI
0.71 to 0.92; p = 0.001).
Varying censoring time
If participants in both groups who did not complete the 12-month visit and did not exacerbate were censored
at their date of last contact (either the 6-month visit date, last post-activation visit date or last completed diary
card date), instead of as described in Table 15, the adjusted hazard ratio was 0.81 (95% CI 0.71 to 0.95;
usual care, n = 860, and modified, n = 850).
If participants in the usual-care group were censored, as described in Table 15, and participants in the modified
self-management group were censored at their date of last contact (i.e. favouring the usual-care group),
the adjusted hazard ratio was 0.93 (95% CI 0.82 to 1.06; usual care, n= 938, and modified, n= 850).
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FIGURE 4 Kaplan–Meier curves for the time to first asthma exacerbation by allocated group.
TABLE 16 Primary outcome: time to first asthma exacerbation
Primary outcome
Intervention arm
Adjusted hazard ratioa (95% CI); p-valueUsual care (N= 938) Modified (N= 933)
Total number (% of total)
with exacerbation
484 (51.6%) 420 (45.0%)
Total follow-up time
(person-years)
610.3 649.8
Rate (per person-years) 0.79 0.65 0.81 (0.71 to 0.92); p= 0.002
a The adjusted hazard ratio was estimated using the Cox proportional hazards model adjusted for randomisation
stratification variables [smoking status and dose of inhaled steroids (high/low), with shared frailty for regional
randomisation centre]. The unadjusted hazard ratio was 0.82 (95% CI 0.72 to 0.94).
Note
Follow-up time is the time to first exacerbation or the time in trial if there was no exacerbation.
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Per-protocol analysis
Just over 50% of participants were included in the per-protocol population: 491 (51%) participants in the
usual-care group and 524 (55%) participants in the modified self-management group (Table 17). A greater
number of participants included in the per-protocol population in the modified self-management group
had an activation to zone 2 or above.
For the participants included in the per-protocol population, 197 in the usual-care group and 189 in the
modified self-management group had an asthma exacerbation, with an adjusted hazard ratio for the time
to first asthma exacerbation of 0.83 (95% CI 0.68 to 1.01; p = 0.06).
Subgroup analysis for the primary outcome
There was no evidence of a difference in the hazard ratio for time to asthma exacerbation in the modified
self-management group compared with the usual-care group according to smoking status or dose of
maintenance inhaled steroid dose at baseline (Table 18).
TABLE 17 Inclusion in the per-protocol population
Inclusion
Intervention arm, n (% of total)
Usual care (N= 965) Modified (N= 957)
Included in per-protocol population 491 (51%) 524 (55%)
Good adherence during the first activation to zone 2 or abovea 233 281
Did not activate zone 2 or aboveb 258 243
a One participant in the modified self-management group was assessed as having good adherence, but was not included
as exacerbated on the same day as randomisation.
b Completed 12-month visit and criteria for activating zone 2 not met.
TABLE 18 Subgroup analysis of time to first asthma exacerbation according to smoking status and dose of
maintenance inhaled steroid dose at baseline
Subgroup
Adjusted subgroup specific
hazard ratio (95% CI)
Adjusted interaction effect
(95% CI)
p-value for interaction
effect
Smoking status
Never smoked 0.78 (0.66 to 0.93) 0.80
Current 0.92 (0.55 to 1.54) 1.18 (0.68 to 2.03)
Former 0.83 (0.67 to 1.04) 1.07 (0.80 to 1.41)
Dose of maintenance inhaled corticosteroids
Low 0.84 (0.72 to 0.98) 0.37
High 0.73 (0.57 to 0.94) 0.87 (0.65 to 1.17)
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Secondary outcomes
Unscheduled health-care consultations and the use of systemic corticosteroids for asthma
Time to first use of systemic corticosteroids for asthma and time to first unscheduled
health consultation for asthma
Figure 5 shows the Kaplan–Meier curves for the time to first use of systemic corticosteroids and the time to
first unscheduled health-care consultation is shown in Figure 6. The adjusted hazards ratios are 0.76 (95% CI
0.65 to 0.88; p< 0.001) for the use of systemic corticosteroids and 0.82 (95% CI 0.70 to 0.92; p= 0.002)
for unscheduled health-care consultations.
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FIGURE 5 Kaplan–Meier curves for the time to first requiring systemic corticosteroids for asthma by allocated group.
0 30 60 90 120 150 180 210 240 270 300 330 365
Days from randomisation
810938
935 824
700
754
624
679
563
596
501
545
376
395
0.00
0.20
0.40
0.60
0.80
1.00
Number at risk
Treatment = usual care
Treatment = modified
Usual care
Modified
Intervention arm
Pr
o
p
o
rt
io
n
 o
f 
p
ar
ti
ci
p
an
ts
 w
it
h
 a
n
 
u
n
sc
h
ed
u
le
d
 h
ea
lt
h
-c
ar
e 
co
n
su
lt
at
io
n
FIGURE 6 Kaplan–Meier curves for the time to first unscheduled health-care consultation for asthma by allocated group.
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Total number of courses of systemic corticosteroids for asthma, unscheduled health
consultations and exacerbations for asthma
Table 19 shows that the number of participants using systemic corticosteroids, having an unscheduled
health-care consultation and an exacerbation (systemic corticosteroids or unscheduled health-care
consultation), was lower in the modified self-management group than in the usual-care group.
Similarly, the total number of courses of systemic corticosteroids, unscheduled health-care consultations
and exacerbations per participant was lower in the modified self-management group than in the usual-care
group (Table 19).
TABLE 19 Summary of unscheduled health-care consultations and use of systemic corticosteroids for asthma
Secondary outcome
Intervention arm
Adjusted intervention effecta
(95% CI)Usual care (N= 939) Modified (N= 935)
Use of systemic corticosteroids
Any courses, n (% of total)
No 552 (59) 614 (66) Risk difference –7.0%
(–11.3% to –2.7%)
Risk ratio 0.83
(0.74 to 0.93)
Yes 377 (40) 311 (33)
Not knownb 10 (1) 10 (1)
Total number of courses n = 929 n= 925 Incidence rate ratio 0.82
(0.70 to 0.96)
Mean (SD) 0.61 (0.93) 0.5 (0.86)
1, n (% of total) 254 (27) 212 (23)
2, n (% of total) 82 (9) 68 (7)
3 or more, n (% of total) 41 (4) 31 (3)
Any unscheduled health-care consultations
Any, n (% of total)
No 490 (52) 543 (58) Risk difference –6.8%
(–11.1% to –2.4%)
Risk ratio 0.86
(0.78 to 0.95)
Yes 442 (47) 379 (41)
Not knownb 7 (1) 13 (1)
Total number of unscheduled
health-care consultations
n = 932 n= 922 Incidence rate ratio 0.86
(0.75 to 0.99)
Mean (SD) 0.84 (1.23) 0.73 (1.19)
1, n (% of total) 261 (28) 224 (24)
2, n (% of total) 96 (10) 83 (9)
3 or more, n (% of total) 85 (9) 72 (8)
Exacerbation: use of systemic corticosteroids and/or unscheduled health-care consultation for asthma
Any exacerbations, n (% of total)
No 445 (47) 499 (53) Risk difference –6.7%
(–11.2% to –2.3%)
Risk ratio 0.87
(0.80 to 0.95)
Yes 485 (52) 422 (45)
Not knownb 9 (1) 14 (1)
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Area under the percentage baseline morning peak flow curve over 2 weeks from the
point of activating zone 2 (or above) of the asthma self-management plan
A higher percentage of participants who activated zone 2 or above of the self-management plan in the modified
self-management group were able to be included in the analysis of the area under the PEF curve analysis (i.e.
54% compared with 41% in the usual-care group) as a result of a higher percentage of participants completing a
diary card in the modified self-management group (Table 20). In both groups, however, there are high numbers
of missing data for this analysis (Table 20). This is mainly due to participants not completing diaries for the first
activation to zone 2 or not recording PEF values on or after day 10.
TABLE 19 Summary of unscheduled health-care consultations and use of systemic corticosteroids for asthma
(continued )
Secondary outcome
Intervention arm
Adjusted intervention effecta
(95% CI)Usual care (N= 939) Modified (N= 935)
Total number of exacerbations n = 930 n= 921 Incidence rate ratio 0.88
(0.77 to 1.01)
Mean (SD) 0.95 (1.29) 0.84 (1.26)
1, n (% of total) 270 (29) 235 (25)
2, n (% of total) 119 (13) 97 (10)
3 or more, n (% of total) 96 (10) 90 (10)
a Adjusted for randomisation stratification variables (smoking status, dose of inhaled steroids and regional centre).
All analysis models include 1874 participants.
b Not known for use of systemic corticosteroids if eCRF page on oral steroid use for asthma reported as unknown or not
completed; not known for unscheduled health-care consultation if eCRF page for health-care consultations for advice on
worsening of asthma symptoms completed as unknown or not completed; and not known for exacerbations if either
eCRF page completed as unknown or not completed and no exacerbation reported on other page or both pages were
completed as unknown or not completed. These participants are included in the analysis models as having no courses of
steroids/health-care consultations/exacerbations (as appropriate) for consistency with the primary analysis where these
participants are censored.
Notes
For participants who did not complete follow-up, information derived up to the time they exited from the trial.
This table also includes data for participants who exacerbated on the same day as randomisation and so were not able to
be included in the analysis of time to first exacerbation.
TABLE 20 Inclusion in analysis of area under percentage baseline peak flow curve over the 2 weeks after activating
zone 2 of asthma self-management plan
Inclusion
Intervention arm, n (% of total)
Usual care (N= 552); at least one
activation to zone 2 or above
Modified (N= 562); at least one
activation to zone 2 or above
Included in analysis 226 (41) 303 (54)
Not included in analysis 326 (59) 259 (46)
Reason not included
No diary for first activation to zone 2 or
above
224 162
No PEF values recorded in diary 24 8
PEF not recorded on day 1 17 17
No PEF recorded on or after day 10 60 72
PEF recorded on day 1 and 10, but no
days in-between
1 –
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For the participants who did record sufficient PEF information on their diary cards, the area under the
percentage baseline PEF curve in the 2 weeks from the point of first activating zone 2 or above of the
self-management plan was slightly higher in the modified self-management group than in the usual-care
group (Table 21).
Change in Mini Asthma Quality of Life Questionnaire 2 weeks after activating zone 2
(or above) of the self-management plan
The percentage of participants who activated zone 2 (or above) of the self-management plan was higher
in the modified self-management group than in the usual-care group and who could be included in the
analysis of change in the Mini AQLQ score (i.e. 51% compared with 39% in the usual-care group) because
of a higher percentage of participants in the former attended the post-activation visit in the modified self-
management group (Table 22). In both groups, however, there are substantial numbers of missing data for
this analysis (Table 22).
TABLE 21 Area under the percentage baseline morning peak flow curve over 2 weeks from the point of first
activating zone 2 (or above) of the asthma self-management plan
Analysis
Intervention arm
Adjusted difference
in meansa (95% CI)
Usual care (N= 552);
at least one activation
to zone 2 or above
Modified (N= 562);
at least one activation
to zone 2 or above
Analysis 1 n= 226 n= 303
Mean (SD) 1130 (155) 1166 (142) 38 (13 to 62)
Median (25th, 75th centiles) 1146 (1025, 1238) 1165 (1073, 1258)
Min., max. 687, 1669 558, 1781
Analysis 2 n= 197 n= 269
Mean (SD) 1133 (152) 1164 (136) 32 (7 to 59)
Median (25th, 75th centiles) 1151 (1030, 1242) 1158 (1069, 1249)
Min., max. 687, 1669 805, 1781
max., maximum; min., minimum.
a Adjusted for randomisation stratification variables and baseline PEF.
Notes
Analysis 1 – participants with a PEF value recorded on day 1, at least one value between day 1 and day 10 and at least one
value on or after day 10. The PEF value was imputed using the last PEF value recorded in the diary for days when PEF was
not recorded.
Analysis 2 – participants with a PEF value recorded on day 1 and day 14 and at least six values between day 1 and day 14.
The PEF value was imputed using the last PEF value recorded in the diary for days when PEF was not recorded.
TABLE 22 Inclusion in the analysis of change in the Mini AQLQ score after activating zone 2 (or above) of the
asthma self-management plan
Mini AQLQ status
Intervention arm, n (% of total)
Usual care (N= 552); at least one
activation to zone 2 or above
Modified (N= 562); at least one
activation to zone 2 or above
Mini AQLQ within 28 days 216 (39) 284 (51)
More than two items
missed, score not calculated
0 1
Mini AQLQ completed after
28 days
36 (7) 40 (7)
Mini AQLQ not done 29 (5) 38 (7)
Post-activation visit not attended 60 (11) 42 (7)
No post-activation record 211 (38) 158 (28)
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For the participants who did complete the Mini AQLQ within 28 days of the first activation to zone 2,
the Mini AQLQ scores were slightly higher in the modified self-management group than in the usual-care
group (Table 23).
Cumulative dose of inhaled and systemic steroids used in the 12 months after
randomisation
Among participants completing the 12-month follow-up visit, the mean total dose of inhaled corticosteroids
used in the 12 months after randomisation was slightly higher in the modified self-management group than
in the usual-care group (Table 24). The mean total dose of systemic corticosteroids taken in this time was
slightly lower in the modified self-management group than in the usual-care group (Table 24) among
participants completing the 12-month follow-up visit. The mean total dose of systemic corticosteroids was
similar in the two groups among participants who took systemic corticosteroids in the 12 months after
randomisation (Table 24).
Serious adverse events
Serious adverse events were reported during the 14-day period following activation of zone 2 (or above) of
the self-management plan. In addition, diagnoses of pneumonia up to 1 month after the 14-day activation
period of zone 2 or above were also considered to be SAEs.
A total of 22 (4%) participants in the usual-care group and 11 (2%) participants in the modified
self-management group who activated zone 2 or above had at least one SAE (Table 25).
Eighteen of the 32 SAEs in the usual-care group were attributable to hospitalisations for asthma, compared
with 3 of the 11 SAEs in the modified self-management group.
There were eight events in the usual-care group and six events in the modified self-management group
relating to pneumonia, lower respiratory tract infections and influenza (Table 25).
One participant in the modified self-management group died after severe pneumonia. This event was not
classified as related to trial treatment.
TABLE 23 Change in Mini AQLQ score 2 weeks after first activating zone 2 (or above) of the self-management plan
Intervention arm Baseline
At post-activation visit following
first activation to zone 2 (or above)
Adjusted difference
in meansa (95% CI)
Usual care
n 216 216
Mean (SD) 5.0 (1.1) 3.9 (1.3)
Modified
n 282 283
Mean (SD) 5.1 (1.2) 4.2 (1.2) 0.2 (0.03 to 0.46)
a Adjusted for randomisation stratification variables and Mini AQLQ score at baseline. A total of 499 participants were
included in the analysis model.
Notes
Mini AQLQ scores range from 1 to 7, higher scores indicating better quality of life.
Participants with a Mini AQLQ completed within 28 days of the first activation to zone 2 were included in the analysis.
A Mini AQLQ was not completed at baseline for one of the participants in the modified self-management group. The mean
baseline score at the participant’s regional centre was used to impute the baseline Mini AQLQ score for this participant for
inclusion in analysis.
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TABLE 24 Cumulative dose of inhaled and systemic corticosteroids used in the 12 months after randomisation
Cumulative dose of corticosteroid
Intervention arm, 12-month visit completed
Usual care (N= 700) Modified (N= 679)
Total dose of inhaled corticosteroids (mg)
Mean (SD) 328.5 (211.8) 385.2 (265.5)
Median (25th, 75th centiles) 292 (146, 365) 304 (178.4, 444.5)
Min., max. 36.5, 1414 29.2, 1592
Total dose of systemic corticosteroids (mg)
Mean (SD) 151.3 (256.9) 120.9 (220.8)
Median (25th, 75th centiles) 0 (0, 210) 0 (0, 200)
Min., max. 0, 2120 0, 1770
Total dose of systemic corticosteroids (mg) in participants who took systemic corticosteroids
n 306 247
Mean (SD) 346.1 (289.3) 332.3 (252.6)
Median (25th, 75th centiles) 240 (150, 400) 210 (180, 400)
Min., max. 25, 2120 15, 1770
max., maximum; min., minimum.
Note
The cumulative dose of inhaled steroids was derived from the information collected at visits (scheduled and post activation)
about permanent asthma medication and from the information entered from the diary cards about inhaler use during
activation to zone 2 or above.
TABLE 25 Summary of serious adverse events
SAE summary
Intervention arm
Usual care (N= 552);
at least one activation
to zone 2 or above
Modified (N= 562);
at least one activation
to zone 2 or above
Number of participants with at least one SAE, n (% of total) 22 (4%) 11 (2%)
Number of SAEs per participant, median (min., max.) 1 (1, 4) 1 (1, 1)
Total number of SAEs 32 11
Serious criterion (not mutually exclusive), n
Fatal 0 1
Life-threatening 0 1
Hospitalisation or prolongation 32 10
Persistent or significant disability/incapacity – –
Congenital anomaly or birth defect – –
Other (ongoing symptoms) 0 1
Classification, n
Serious, not related to trial treatment 31 10
Serious, possibly related to trial treatment 0 1
Not reportable per protocol 1 0
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One of the 11 SAEs in the modified self-management group was classified as possibly related to trial
treatment. This participant had pneumonia (outside the 14-day period following activation to zone 2) and
had fourfolded their usual medication (4000 µg) on two occasions (once for 7 days and one for 6 days)
prior to the event.
Non-serious adverse events
Non-serious AEs were reported during the 14 days following activation of zone 2 of the self-management
plan. Only adverse events that are known side-effects of inhaled corticosteroids, such as oral candidiasis
(i.e. thrush) and dysphonia (i.e. hoarseness), were intended to be collected from discussion with the
participant and information from the diary card.
Ten (2%) participants in the usual-care group and 41 (7%) participants in the modified self-management
group who activated zone 2 or above had at least one non-serious AE (Table 26). Of the 56 non-serious
AEs in the modified self-management group, 44 were classified as definitely or probably related to inhaled
corticosteroids, compared with 6 of the 13 non-serious adverse events in the usual-care group. The breakdown
of the type of events is shown in Table 26.
TABLE 25 Summary of serious adverse events (continued )
SAE summary
Intervention arm
Usual care (N= 552);
at least one activation
to zone 2 or above
Modified (N= 562);
at least one activation
to zone 2 or above
SAE description (MedDRA-preferred term), n
Asthma 18 3
Pneumonia 1 5
Lower respiratory tract infection 3 –
Influenza 1 1
Lobar pneumonia 2 –
Oesophageal candidiasis 2 –
Acute myocardial infarction – 1
Allergy to animal 1 –
Atelectasis 1 –
Cardiac failure congestive – 1
Gastroenteritis viral 1 –
Pneumonia bacterial 1 –
Renal impairment 1 –
max., maximum; min., minimum.
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TABLE 26 Summary of non-serious adverse events
Non-serious AE summary
Intervention arm
Usual care (N= 552); at least one
activation to zone 2 or above
Modified (N= 562); at least one
activation to zone 2 or above
Number of participants with at least
one non-serious AE, n (% of total)
10 (2%) 41 (7%)
Number of non-serious AEs per
participant, median (min., max.)
1 (1, 2) 1 (1, 4)
Total number of non-serious AEs 13 56
Relationship to inhaled steroids, n
Definitely 3 17
Probably 3 27
Possibly 2 8
Not related 5 4
Severity, n – –
Mild 7 31
Moderate 6 24
Severe 0 1
AE description (MedDRA-preferred term), n
Oral candidiasis 7 19
Dysphonia 2 17
Asthma 2 2
Candidiasis – 4
Oral pain – 4
Oropharyngeal pain – 4
Lower respiratory tract infection 1 1
Adverse drug reaction – 1
Dry throat – 1
Laryngitis 1 –
Mouth ulceration – 1
Oral herpes – 1
Pharyngitis – 1
max., maximum; min., minimum.
Notes
In addition to the events above, four other adverse events not considered to be known side effects of inhaled steroids were
also reported (MedDRA-preferred terms of radius fracture, myalgia, diarrhoea and vomiting).
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Chapter 4 Health economics analysis
Introduction
The cost-effectiveness analysis (CEA) was conducted alongside the FAST to establish the value for money
of temporarily quadrupling the dose of inhaled corticosteroid compared with usual care.
The objectives of the CEA were to:
1. identify the related costs associated with delivering the treatments
2. measure the participants’ use of respiratory-related health and social care services
3. compare the estimated mean cost per participant between the two intervention groups
4. estimate the health benefits of the trial interventions using QALYs calculated from the EQ-5D-3L
questionnaire and the number of exacerbations prevented
5. compare the cost difference between the two intervention groups with difference in effectiveness and
generate incremental cost-effectiveness ratios (ICERs)
6. test the uncertainty of the calculated ICERs, using the bootstrapping method, and generate cost-
effectiveness acceptability curves (CEACs) to demonstrate the probability of the modified treatment
being cost-effective over and above usual care.
Methods
Following the National Institute for Health and Care Excellence (NICE)’s Guide to the Methods of Technology
Appraisal 2013,15 the analysis was conducted from the NHS/Personal Social Services perspective, with costs
expressed in Great British pounds (£) for the financial year 2014–15.15 A total of 1922 participants were
randomised; however, 51 of these participants were excluded as they had no information from randomisation.
The follow-up for the analysis was 6 months and 12 months from randomisation. All costs were inflated to
2014–15 price levels, where necessary, using the Hospital and Community Health Services pay and price
inflation index.16,17 No discount rate was applied as the follow-up was 12 months.
Treatment costs
A micro-costing exercise was conducted following the methods of technology appraisal recommended by
NICE.15 Treatment costs consisted of the total inhaled corticosteroid use during the 14-day activation period.
This was calculated from the self-reported diary card and the number of extra corticosteroid inhalers provided.
The number of puffs on each day was recorded on the diary card and these doses were rounded up to the
nearest inhaler, depending on the number of doses for each particular inhaler, and costed using prescription
cost analysis (PCA).18 Where the information was missing from the diary card, the adherence, as assessed
by the nurse, was used to estimate the total amount of inhaled corticosteroid use in the 14-day period.
All participants in the modified self-management group who used a combination inhaler were given at least
one extra corticosteroid inhaler, these were costed accordingly using the PCA. Any trial-related costs were not
included in the analysis.
Unit costs of respiratory-related resource use
Respiratory-related health-care utilisation was collected for each participant alongside the trial. This was
recorded using a comprehensive service-use questionnaire at 6 months and 12 months. Some questionnaires
were not delivered at the correct follow-up time points, so a leeway of ± 2 months was used to decide those to
be included and those to be considered missing. Wider societal costs were also collected, including travel time
and productivity loss. However, as a result of the poor report rate, because of the burden of the questionnaire,
only a tentative exploration of the potential impact of these costs could be made with the data available.
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National unit costs were applied to the recorded resource use from a range of published sources. Table 27
shows the unit costs employed to generate a total respiratory-related resource cost per participant. The
majority of the unit costs were from the Personal Social Services Research Unit’s Unit Costs of Health and
Social Care 201517 and the Department of Health and Social Care (DHSC)’s NHS Reference Costs 2014/15.19
Prescriptions were costed using the PCA and a weighted average unit cost for each drug was applied.18
Health outcome measures
In addition to the clinical outcomes collected in the statistical analyses, health benefits were measured in
QALYs for the economic evaluation. QALYs are a generic measure of health that can be used to compare
across all interventions, and are not constrained to just asthma-related treatment. QALYs were derived
by calculating the area under the curve, using utility scores measured by the EQ-5D-3L questionnaire at
baseline, and at the 6- and 12-month follow-ups.23 As well as QALYs, the economic evaluation also presents
cost-effectiveness results based on the total number of exacerbations per participant in the 12-month period.
Cost-effectiveness analysis
Incremental cost-effectiveness analysis was performed to combine the costs of the interventions with the
outcomes. To generate an ICER, the mean difference in costs between the two intervention groups is
divided by the mean difference in effect. The formula below is for the ICER, where Δ represents difference,
E represents effects and C represents the cost of the intervention, and subscripts ‘I’ and ‘UC’ refer to
intervention and usual care, respectively:24
ICER =
ΔC
ΔE
=
CI −CUC
EI − EUC
. (1)
An ICER is not needed if the treatment is both more clinically effective and less costly; in this instance the
treatment is said to be dominant.
TABLE 27 Respiratory-related wider health-care unit costs
Item Unit cost (£) Source
GP visit 37.00 Curtis17
PN visit 12.00 Curtis17
GP visit (at home) 75.00 Curtis17
PN visit (at home) 21.00 Curtis17
Other primary care costs incurred 61.00 Curtis17
Walk-in centre 54.00 Curtis17
Inpatient (visits) 526.00 DHSC’s NHS Reference Costs 2014–1519
Outpatient (visits) 169.00 DHSC’s NHS Reference Costs 2014–1519
A&E (visits) 132.00 DHSC’s NHS Reference Costs 2014–1519
Emergency ambulance (journeys) 231.00 Curtis17
Patient transport services (journeys) 35.00 DHSC’s NHS Reference Costs 2009–1020
111 call 3.55 Curtis;17 NHS employers’ Agenda for Change Pay Bands and Points
from 1 April 2014;21 and NHS England’s NHS 111 Statistics –
March 201522
A&E, accident and emergency; PN, practice nurse.
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Handling uncertainty
The non-parametric bootstrap re-sampling technique was employed to explore the sensitivity of calculated
ICERs.25–28 Cost and outcome data were bootstrapped to account for skewness, sampling with replacement
observations 5000 times to generate a new population of sample means with an approximate normal
distribution. These bootstrap results were then displayed graphically using a cost-effectiveness plane (CEP)
to show the uncertainty surrounding the mean estimates of incremental costs and effects, and a CEAC to
show the probability of the treatment being cost-effective at different thresholds. To assess the uncertainty
surrounding the ICER, bootstrapped 95% CIs were generated.
Handling missing data
In terms of missing data, 29% in the usual-care group and 32% in the modified self-management group
were missing the QALY outcome. In total, 1% in each group were missing the number of exacerbations
outcome, 30% in the usual-care and 26% in the modified self-management group were missing the
6-month costs and 35% in the usual-care and 36% in the modified self-management group were missing
the 12 month’ costs (including those lost to follow-up).
Missing data for outcomes and costs were handled by using Rubin’s multiple imputation (MI) method,24,29,30
assuming that any missing data were missing at random.
Sensitivity analysis
A sensitivity analysis was undertaken to repeat the CEA using complete cases, that is, only those participants
who had both cost and outcome data at the same time were included. This was done separately for the
two outcome measures. Owing to questionnaires being delivered outside the specified 6- and 12-month
time points, a 2-month leeway was applied to the primary analysis. To test the robustness of this, a second
sensitivity analysis was done with just a 1-month leeway, putting all those participants who exceeded this as
missing. The third sensitivity analysis was to include reliever inhaler costs, as reported on the diary card, in the
total costs.
Results
A total of 1922 participants were recruited to the trial, with 51 excluded, leaving 1871 participants analysed
in the economic evaluation (935 in the modified self-management group and 939 in the usual-care group).
The base-case CEA was based on a MI data set, in which all the missing values were imputed using the
MI method.
Costs
The intervention costs reported in Table 28 reflect the value of pharmacological resources needed to
deliver the intervention. The mean cost per participant was £42 [standard error (SE) £2] for the modified
self-management group and £17 (SE £1) for the usual-care group. This resulted in an adjusted difference
of £25 (p < 0.001).
Respiratory-related resource-use costs were similar between interventions, with the modified self-management
group costing slightly less, at £415 (SE £42) compared with £431 (SE £43), driven by the lower cost of resource
use at 6 months (£168, SE £16). After adjusting for baseline characteristics, this resulted in a difference of
–£24 (bootstrapped 95% CI –£122 to £71). Total resource cost included the cost of the two deaths, one in
each intervention group. The death in the modified self-management group was costed using the five nights
spent in hospital for pneumonia and the unit cost per night from the reference costs (£373).20 The death in
the usual-care group was sudden and the participant died at home, so the cost of an ambulance call-out was
used as a conservative estimate (£231). The costs of deaths added £0.25 (SE 0.25) per participant and £1.99
(SE £1.99) to the cost per participant in the usual-care and modified self-management groups, respectively.
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The modified self-management group had a lower total reported cost than the usual-care group, mostly
driven by the difference in health-care resource use. This resulted in the modified self-management plan
being £24 (bootstrapped 95% CI –£71 to £122) less costly than usual care; however, this difference did
not reach statistical significance (p = 0.681).
Outcomes: quality-adjusted life-years and number of exacerbations
The primary health economic outcome was QALY gains over 12 months, which were estimated using the
EQ-5D-3L. Table 29 reports mean EQ-5D-3L scores at baseline, and at 6 and 12 months. There was little
difference between the intervention arms in EQ-5D-3L scores at baseline and both intervention arms saw a
decline in score over the study period. The resulting difference in QALYs was 0.02 (bootstrapped 95% CI
–0.005 to 0.04) greater for the modified self-management group, after adjusting for baseline EQ-5D-3L
scores and characteristics; however, this difference did not reach statistical significance (p = 0.207).
The second health outcome, also assessed in the statistical analysis, was the number of exacerbations over the
12-month study period. Table 30 shows that the usual-care group has a higher mean number of exacerbations
(0.95, SE 0.04 exacerbations) than the modified self-management group (0.84, SE 0.04 exacerbations) with an
adjusted difference of –0.10 exacerbations (bootstrapped 95% CI –0.21 to 0.01 exacerbations), although this
finding did not reach statistical significance (p = 0.080).
TABLE 28 Multiple imputation: cost results
Cost (£)
Intervention arm
Usual care (N= 939) Modified (N= 935)
Intervention, mean (SE) 17 (1) 42 (2)
Resource use at 6 months, mean (SE) 215 (123) 168 (16)
Resource use at 12 months, mean (SE) 198 (28) 203 (38)
Total resource use,a mean (SE) 413 (42) 372 (42)
Total cost, mean (SE) 431 (43) 415 (42)
Adjusted differenceb (bootstrapped 95% CI) –24 (–122 to 71); p= 0.681
a Includes cost of death.
b Adjusted for age, sex, smoking status, inhaled corticosteroid use and site as random effects.
TABLE 29 Multiple imputation: QALY results
Time point
Intervention arm
Usual care (N= 939) Modified (N= 935)
EQ-5D-3L scores, mean (SE)
Baseline 0.79 (0.01) 0.80 (0.01)
6-month follow-up 0.72 (0.01) 0.75 (0.01)
12-month follow-up 0.72 (0.01) 0.74 (0.01)
QALYs, mean (SE) 0.74 (0.01) 0.76 (0.09)
Adjusted differencea (bootstrapped 95% CI) 0.02 (–0.00 to 0.04); p = 0.207
a Adjusted for baseline EQ-5D-3L score, age, sex, inhaled corticosteroid use, smoking status and site as random effects.
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Cost-effectiveness analysis and uncertainty
Two sets of cost-effectiveness analyses were conducted using QALYs and the number of exacerbations per
participant. As the modified treatment was both less costly and more effective for both health outcomes,
the modified treatment is said to be ‘dominant’. However, Table 31 reflects the uncertainty with this result,
as shown by the 95% bootstrapped CIs.
However, the difference between costs, QALYs and exacerbations was not statistically significant.
This suggested that there is significant uncertainty surrounding these estimates. To investigate this,
a non-parametric bootstrapping technique was investigated. A cost-effectiveness scatterplot was produced
from the bootstrapping results for difference in QALYs and difference in cost and then, again, for
difference in exacerbations and difference in cost. The results of the 5000 re-samples for each outcome
were plotted on a cost-effectiveness plane (Figure 7), visually displaying any uncertainty surrounding the
mean differences in costs and benefits between the intervention and usual-care groups. The CEP in Figure 7a
shows the majority of the plots falling in the south-east quadrant (65%), suggesting greater QALYs and lower
costs for the modified self-management group. With 29% of the plots falling in the north-east quadrant,
there is some uncertainty surrounding the costs; however, the majority of plots fall below both the
£30,000- and £20,000-threshold line, implying a high probability of cost-effectiveness for the modified
self-management group.
Figure 7b shows the majority of the plots falling in the west quadrants, suggesting a positive health gain in
terms of exacerbations prevented, but also uncertainty in terms of costs with plots falling in both the north
and south quadrants.
Using the bootstrapped replicates we also generated a CEAC (Figure 8), which provides a plot of probabilities
that the intervention was cost-effective (y-axis) against all potential values of willingness-to-pay thresholds
(x-axis). This can be generated only for the QALY outcome, as there is not a threshold for exacerbations
prevented. The CEAC (Figure 8) shows that, with a willingness-to-pay threshold of £20,000, there is a 94%
chance of the intervention being cost-effective.
TABLE 31 Results of CEA
CEA results
Intervention arm
Difference in mean
(bootstrapped 95% CI)Usual care (N= 939) Modified (N= 935)
Total cost, mean (SE) £431 (£43) £415 (£42) –£24 (–£122 to £71)
QALY, mean (SE) 0.74 (0.01) 0.76 (0.09) 0.02 (–0.00 to 0.04)
Exacerbations, mean (SE) 0.95 (0.04) 0.84 (0.04) –0.10 (–0.21 to 0.01)
ICER
QALY (bootstrapped 95% CI) Dominant (–£21,699 to £16,268)
Exacerbations (bootstrapped 95% CI) Dominant (–£1999 to £2492)
TABLE 30 Multiple imputation: exacerbation results
Exacerbations
Intervention arm
Usual care (N= 939) Modified (N= 935)
Number of exacerbations, mean (SE) 0.95 (0.04) 0.84 (0.04)
Adjusted difference (bootstrapped 95% CI) –0.10 (–0.21 to 0.01); p= 0.080
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Complete-case analysis (sensitivity analysis)
In order to explore the potential impact of missing data on the results, a sensitivity analysis was conducted
using complete cases. Complete costs and QALYs were available for 1041 participants and complete costs
and the number of exacerbations were available for 1047 participants.
Table 32 shows the complete-case analysis results for complete QALYs and costs. As with the primary
analysis, the results were cost-saving (–£109, bootstrapped 95% CI –£259 to £41; p = 0.148) and not
statistically significant. The results of the QALYs showed a lower difference, of 0.01 (bootstrapped
95% CI –0.02 to 0.04; p = 0.517), compared with 0.02 in the primary analysis. However, the results did
not reach statistical significance.
Table 33 shows the complete-case results for the number of exacerbations. As with the complete-case
results for the QALYs, the costs for the complete exacerbations results were cost-saving, with an
TABLE 32 Complete-case analysis: QALYs
Costs and QALYs
Intervention arm
Usual care (N= 512) Modified (N= 529)
Intervention, mean (SD) £22 (£34) £51 (£74)
Resource use at 6 months, mean (SD) £240 (£766) £139 (£275)
Resource use at 12 months, mean (SD) £220 (£920) £191 (£853)
Total service use,a mean (SD) £461 (£1459) £333 (£930)
Total cost, mean (SD) £483 (£1464) £384 (£943)
Adjusted difference (bootstrapped 95% CI) –£109 (–£259 to £41); p= 0.148
EQ-5D-3L scores, mean (SD)
Baseline 0.80 (0.26) 0.82 (0.23)
6-month follow-up 0.80 (0.26) 0.82 (0.23)
12-month follow-up 0.81 (0.26) 0.81 (0.24)
QALYs, mean (SD) 0.80 (0.23) 0.82 (0.21)
Adjusted difference (bootstrapped 95% CI) 0.01 (–0.02 to 0.04); p= 0.517
a Includes cost of death.
TABLE 33 Complete-case analysis: exacerbations
Costs and exacerbations
Intervention arm
Usual care (N= 514) Modified (N= 533)
Intervention, mean (SD) £23 (£34) £50 (£74)
Resource use at 6 months, mean (SD) £239 (£765) £138 (£274)
Resource use at 12 months, mean (SD) £219 (£918) £191 (£850)
Total service use,a mean (SD) £459 (£1457) £333 (£927)
Total cost, mean (SD) £482 (£1461) £383 (£940)
Adjusted difference (bootstrapped 95% CI) –£110 (–£265 to £39); p= 0.144
Exacerbations, mean (SD) 1.07 (1.34) 0.90 (1.30)
Adjusted difference (bootstrapped 95% CI) –0.18 (–0.34 to –0.02); p= 0.046
a Includes cost of death.
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adjusted difference of –£110 (bootstrapped 95% CI –£265 to £39; p = 0.175). The complete-case results
for the number of exacerbations showed a greater difference in the number of exacerbations, with an
adjusted difference of –0.18 (bootstrapped 95% CI –0.34 to –0.02) and the results did reach statistical
significance (p = 0.046).
The modified self-management group had lower costs and better health outcomes; therefore, the modified
treatment was said to be ‘dominant’. However, the cost and QALY difference were not statistically significant,
so CEPs were used to explore this uncertainty. Figure 9 shows the CEP for QALYs and for exacerbations on
the left-hand side and for exacerbations on the right-hand side. The majority of the plots in the CEP in
Figure 9a fall in the south-east quadrant (71%), inferring lower costs and greater QALYs for the modified
self-management group. However, compared with the base case, more plots fall in the south-west quadrant
(21% vs. 4%), where both incremental costs and effects are negative. The majority of plots fall below both
the £30,000- and £20,000-threshold line, suggesting a high probability of cost-effectiveness. The CEP in
Figure 9b shows certainty in reducing exacerbations, with the majority of the plots falling in the west
quadrants, which was also reflected in the significant p-values. The CEAC in Figure 10 shows an 86%
probability of the intervention being cost-effective at a threshold of £20,000.
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Sensitivity analysis
Table 34 presents the MI results of changing the questionnaire leeway to 1 month. For the usual-care group
this resulted in 59% missing data and for the modified self-management group 56% missing data. The results
showed a lower cost difference (–£10, bootstrapped 95% CI –£94 to £74) and a lower QALY difference
(0.01, bootstrapped 95% CI –0.01 to 0.03). The difference in exacerbations remained the same.
The reliever inhaler costs were very small (modified £0.86, SE £0.04; usual care £0.78, SE £0.04) per
participant and, therefore, made very little difference to total costs.
Details of the wider societal costs analysed in the trial are presented in Appendix 7.
Summary/conclusion
This economic evaluation assessed the cost-effectiveness of temporarily quadrupling the dose of inhaled
corticosteroid compared with usual care.
The mean intervention cost was £42 (SE £2) per participant in the modified self-management group and
£17 (SE £1) per participant in the usual-care group. Taking into consideration the wider respiratory-related
health-care resource use, participants who received the modified treatment had non-significantly lower
total mean costs over the 12-month period after adjusting for covariates. The adjusted total cost difference
was –£24 (bootstrapped 95% CI –£122 to £71).
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FIGURE 10 Cost-effectiveness acceptability curve (complete case) for 12 months.
TABLE 34 Sensitivity analysis results: 1-month leeway
Summary
Intervention arm, mean (SE)
Adjusted difference (bootstrapped 95% CI)Usual care (N= 939) Modified (N= 935)
Total cost £404 (£41) £402 (£39) –£10 (–£94 to £74)
QALY 0.79 (0.01) 0.80 (0.01) 0.01 (–0.01 to 0.03)
Exacerbations 0.95 (0.04) 0.84 (0.04) –0.10 (–0.22 to 0.00)
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It is recommended by NICE that cost-effectiveness be expressed in terms of cost per QALY. In this study,
there was a non-significant trend towards higher QALYs associated with the modified treatment (adjusted
difference of 0.02, bootstrapped 95% CI –0.005 to 0.04). The economic evaluation also used the number
of exacerbations. There was, once again, a non-significant trend towards fewer exacerbations associated
with the modified treatment (adjusted difference of –0.10, bootstrapped 95% CI –0.22 to 0.01).
The base-case results were based on a MI data set. As the modified treatment was both more effective and
less costly, it was said to be ‘dominant’ in terms of both QALYs and the number of exacerbations prevented.
Although the differences in QALYs and costs were not statistically significant, the CEAC demonstrated a
94% probability of it being cost-effective at a £20,000 threshold.
A sensitivity analysis was carried out using complete cases to explore the impact of missing data. The results
showed a lower cost for the modified self-management group and higher cost for the usual-care group,
resulting in the modified treatment still being cost-saving for both the exacerbation complete-case analysis
(adjusted difference of –£110, bootstrapped 95% CI –£265 to £39) and the QALY complete-case analysis
(–£109, bootstrapped 95% CI –£259 to £41). However, the difference in QALYs was reduced, resulting
in the modified self-management group being less effective than in the base case (adjusted difference of
0.01, bootstrapped 95% CI –0.02 to 0.04). On the other hand, the difference in exacerbations was greater
and statistically significant (adjusted difference of –0.18, bootstrapped 95% CI –0.34 to –0.02), unlike the
base-case analysis. As both health outcomes saw greater improvement and lower costs than usual care,
the modified treatment was said to be ‘dominant’. However, this should be interpreted with caution as the
cost difference did not reach statistical significance and the CEPs demonstrate the uncertainty surrounding
this result.
Including reliever inhaler costs within the intervention cost made little difference to the results, as these
costs were so small. Changing the leeway of the questionnaires to 1 month, from 2 months, decreased the
adjusted total cost difference to –£10 (bootstrapped 95% CI –£94 to £74) and reduced the QALY difference
to 0.01 (bootstrapped 95% CI –0.01 to 0.03). However, changing the leeway of the questionnaires did
not change the direction of the results and it still had an 87% chance of being cost-effective at a threshold
of £20,000.
An exploration of wider societal costs was carried out with the available data. On the whole, there
was little difference between the intervention groups, with slightly greater costs seen for the modified
self-management group. However, some of this greater cost was due to one participant reporting very
high travel costs. Although conclusions could not be drawn because of missing data, the exploration
suggested that there may be costs incurred by participants as a result of hospital and GP visits.
In conclusion, the economic evaluation of the FAST has provided us with evidence showing that quadrupling
the inhaled corticosteroid use during the activation zone results in better clinical outcomes. Moreover, the
CEA shows that this intervention is likely to be a cost-effective intervention in comparison with usual care.
HEALTH ECONOMICS ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Chapter 5 Discussion
Summary/conclusion
Our results demonstrate that a self-management plan that recommends a temporary quadrupling of
inhaled corticosteroids at the time of deteriorating asthma control can prevent asthma exacerbations,
compared with the usual self-management plan. This supports the findings from a previous trial.6
Overall, 51.6% of the usual-care self-management group had an asthma exacerbation (defined as the need
for systemic corticosteroids and/or unscheduled health-care consultation) at least once in the 12-month study
period, compared with 45% of the modified self-management group, with an adjusted hazard ratio for time
to first exacerbation of 0.81 (95% CI 0.71 to 0.92; p = 0.02). This equates to 15 patients needing to be given
the modified self-management plan for one additional patient to benefit (i.e. avoid an asthma exacerbation,
95% CI 9 to 43 patients). There was no evidence in the subgroup analysis that the intervention effect
differed for the time to first exacerbation according to inhaled corticosteroid dose or smoking status.
Each of the 12 secondary outcomes favoured the modified treatment group. There were fewer participants
who were prescribed systemic corticosteroids and attended unscheduled health-care consultations in the
modified self-management group than in the usual-care self-management group. However, there was a large
number of missing data for some secondary outcomes (i.e. peak flow and the Mini AQLQ) which limited
confidence in the findings. However, the results were in keeping with the primary outcome and secondary
outcomes for which data completion was greater, providing some reassurance around their reliability.
The safety data continued to support the clinical benefit of a temporary fourfold increase in of inhaled
corticosteroids as participants in the modified treatment group reported fewer asthma-related hospitalisations
(three in the modified self-management group compared with 18 in the usual-care group). The modified
self-management group did experience a higher frequency of treatment-related side effects of inhaled
corticosteroids, such as oral thrush (56 events reported by 41 participants in the modified self-management
group and 13 events reported by 10 participants in the usual-care group), but this was expected because of
the nature of the intervention. Local adverse effects such as these are not usually a major problem and are
usually easily treated with local therapy. Of more concern are reports of pneumonia, especially in patients
with COPD, and adverse effects related to systemic absorption, such as adrenal suppression, osteoporosis
and cataract. The median dose of inhaled corticosteroid in our study was 800 mcg/day, so quadrupling
this would equate to the equivalent of 3200 mcg/day of inhaled beclometasone. Unfortunately, the
systemic effects of high-dose inhaled corticosteroids are not well described and the dose potency in terms
of prednisolone equivalents appears to vary from tissue to tissue.31 In terms of milligrams of prednisolone,
adrenal suppression from 1.5 mg/day of fluticasone (approximately 3 mg of beclometasone) has been
estimated to have approximately the same effects on morning cortisol suppression as between 10 and 20mg
of prednisolone.31 As the study included patients on 2000 mcg of inhaled fluticasone, and if the dose potency
ratio between fluticasone propionate and prednisone is linear, then the quadrupled dose could have the
same systemic effects as a course of prednisolone used to treat asthma exacerbations.
Finally, although there have been reports of an increased risk of respiratory infections in patients on
long-term high-dose inhaled steroids,32 the study found no evidence of an increased incidence of pneumonia.
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Health economics
To date, FAST is the first large randomised controlled trial that has assessed the cost-effectiveness of
temporarily quadrupling the dose of inhaled steroid to reduce asthma exacerbations.
When using QALYs as a standard health outcome measurement, the modified treatment was said to be
‘dominant’. When using the NICE decision threshold of £20,000–30,000, the modified treatment had a
94–95% probability of being cost-effective. The complete-case analysis also showed a 86% probability
of the modified treatment being cost-effective at a threshold of £20,000; however, this probability decreased
as the threshold increased. This is because the complete-case results had more plots falling into the south-
west quadrant (i.e. less costly and less effective). The CEAC assumes that the amount saved in order to give
up one QALY increases with the threshold. Therefore, more plots were excluded in the south-west quadrant
as this threshold increased. This led to a lower probability of cost-effectiveness at higher thresholds, as many
plots fell into the south-west quadrant.
When using the number of exacerbations as the health outcome, the modified treatment was once again
‘dominant’. However, as no decision-making threshold exists, the probability of cost-effectiveness could
not be assessed.
Reducing the number of exacerbations per participant should lead to fewer hospitalisations, which account
for the greatest cost of wider health care. A lower number of hospitalisations was reported at 6 months for
the modified self-management group and was reflected in the much lower cost at this follow-up; however,
this did not persist through to the 12-month follow-up and the overall difference in resource-use costs was
not statistically significant. This may suggest that the overall reduction in the number of exacerbations was
not great enough to make a significant impact on hospital admissions, but over a longer period of time this
may accumulate a greater cost-saving. This may have also been impacted by an imbalance at baseline, but
as the study did not collect baseline costs the analyses still need to be interpreted with caution.
The strength of the economic analysis has been impacted by a few limitations of the study. First, there
was no baseline service-use questionnaire. Although the randomisation ensures that characteristics and
confounders are balanced between the groups at baseline, it may not have been balanced for health-care
service use. The questionnaires were also not always delivered at the right time, and so assumptions had
to be made as to what was considered an appropriate time frame and data were lost because of this. For
the intervention costing, only what was reported on the diary cards could be used. It is, therefore, possible
that some participants may have activated but not recorded their inhaler use and the study would not have
been able to cost this. Once more, nine participants in the usual-care group were reported being given
extra steroid inhalers and self-reported using them on their diary cards, so there might have been some
crossover between groups.
Relevance to existing literature
In June 2016, the Cochrane review relating to whether or not an increase in corticosteroid inhalers at the
first sign of asthma exacerbation is better than, and as safe as, continuing with the usual prescribed inhaled
corticosteroid dose was updated.33 From the eight studies included (1669 participants with mild to moderate
asthma) the authors concluded that it is unlikely that increasing the dose of inhaled corticosteroid reduces
the need for courses of systemic corticosteroids, hospitalisations or recovery time. The Cochrane review
made it clear that its results were rated as being moderate to low quality, as the findings were uncertain
across the studies and the studies conducted included very few participants in whom it could definitively be
shown that increasing the dose was beneficial.
DISCUSSION
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The benefit of an increase in inhaled corticosteroid treatment at the time of asthma control worsening is
also supported by the benefit seen from studies evaluating Symbicort for maintenance and relief medication.
Studies have shown that a variable dose of Symbicort, for use only by patients whose asthma becomes
severe or whose asthma symptoms start to worsen, results in fewer acute exacerbations than a constant
dose of maintenance treatment.
Strengths and limitations
This was an adequately powered RCT, with high follow-up rates for the primary outcome and a moderate
adherence to the trial intervention.
The trial was open-label to research site staff and participants so, although the possibility cannot be ruled
out that the treatment effect in the modified treatment group was enhanced, the inclusion of any placebo
effect makes the study more relevant to real-life clinical practice.
The diary card completion of participants with at least one activation to zone 2 or above was not balanced
between the two groups, with poorer completion noted in the usual-care self-management group than
in the modified self-management group. This could have contributed towards a null bias, which could
strengthen the positivity of the result. Overall, diary cards were not completed for the first activation to
zone 2 by 34% of participants; this meant that information was unknown about adherence to the allocated
self-management plans for 39% of participants in the usual-care group and 28% of participants in the
modified self-management group.
A large number of missing data were missing for the secondary outcomes of area under peak flow curve
and change in the Mini AQLQ score 2 weeks after activating zone 2 or above of the self-management
plan. In addition, there was an imbalance in the number of participants with these outcomes available in
the two allocated groups. Reassuringly, the results were consistent with the findings where more complete
data were available, but these analyses still need to be interpreted with caution because of the potential
risk of bias attributable to the missing data.
Finally, additional information on the acceptability of carrying an additional inhaler for the 80% of patients
on a combination inhaler would have been useful information to have collected. Although no evidence
was found that this led to early withdrawal from the study, it would be interesting to know how acceptable
this would be for patients in real life as it could represent a barrier to the widespread use of such a
self-management plan.
Generalisability
The study has good external validity as it was a pragmatic design that reflected normal clinical practice
across both primary and secondary care in the UK. Participants used their existing asthma medication,
and those in the modified self-management group either increased the dose of their corticosteroid
inhaler or added an extra corticosteroid inhaler, depending on whether their usual treatment comprised
corticosteroid or a combination of corticosteroid/long-acting beta agonist inhaler. It is important to note
that throughout the trial the site staff ensured that the self-management plans were well explained and
supported, and if this was not carried through into routine care the results may not apply.
Participants were recruited from 207 UK centres, both hospitals and GP surgeries, covering a range of urban
and rural settings. This trial included people aged ≥ 16 years with chronic asthma who had had at least one
acute exacerbation in the previous 12 months. The trial was inclusive of patients who were prescribed to
the upper limit of the licensed dose of their maintenance steroid, so participants on very high doses of
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maintenance steroids were included in the trial. The study identified a group of patients at risk of further
exacerbation and, therefore, with most to gain from following a self-management plan.
It is important to note that the exacerbation rate in the usual-care group was higher than expected,
which suggests that the study recruited a sample of patients whose asthma was more severe than initially
anticipated. So despite the percentage of participants on the modified self-management plan having an
exacerbation being lower than that in the usual-care group, the overall exacerbation was still high (45%).
As children were not included in this study it is not known if this intervention would be beneficial to treat
asthma symptoms in children.
DISCUSSION
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Chapter 6 Conclusions
Main conclusions
This is the largest independent randomised controlled trial to assess the clinical effectiveness and
cost-effectiveness of an asthma self-management plan that advises participants to increase fourfold their
inhaled corticosteroid at the point at which asthma symptoms deteriorate. Both the clinical and economic
analyses show this approach to asthma control to be effective for participants and health providers.
Implications for practice
The trial has shown that the use of an asthma self-management plan that advises patients to quadruple their
dose of inhaled corticosteroid at the point of asthma deterioration is effective in reducing exacerbations that
require unscheduled health-care consultations and the use of systemic corticosteroids in those patients who
identify as having exacerbated within the last year, as well as proving cost-effective for health-care providers.
Although quadrupling the corticosteroid dose appeared to be clinically effective and cost-effective across
the licensed dose range, the systemic effects resulting from this advice in patients using high-dose inhaled
corticosteroids need to be considered, and widespread adoption in these patients is not recommended.
Clinical commissioners and national and international guideline developers can now be encouraged to make
informed decisions regarding the use of self-management plans that advise a fourfold increase in inhaled
corticosteroid dose on the basis of these robust findings. As only 15 patients need to be trained to use such
a self-management plan to prevent one severe exacerbation, the study showed that all patients on low to
medium doses of inhaled corticosteroids, especially if they have had an exacerbation in the last year, should be
encouraged to follow such a plan.
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Appendix 3 The Fourfold Asthma STudy’s asthma
self-management plans
Modified
Usual care
ZONE 1 ZONE 2 ZONE 3 ZONE 4 
Your asthma is under control if: 
• You have no or minimal symptoms during
the day and night (wheezing, coughing, 
shortness of breath or tightness in the chest) 
• You can do all of your normal activities 
without asthma symptoms 
• Your peak flow reading is normal or near
normal for you: ______ 
Your asthma is getting worse if you have
ONE or MORE of the following:
• You need your reliever inhaler more than 
usual 
• You have more  difficulty sleeping because
of your asthma
• Your peak flow is below _______
Your asthma is much more severe if you 
have ONE or MORE of the following: 
• You need to take your reliever inhaler 
every four hours or more often 
• You are unable to manage your normal
activities 
• You have symptoms during the day or
night 
• Your peak flow reading is below ______
It is an asthma emergency if any of the 
following happen: 
• Your reliever inhaler (usually blue) does
not help. 
• One or more of your symptoms get worse 
(wheezing, coughing, shortness of breath or
tightness in the chest)
• You are too breathless to speak 
• Your peak flow reading isbelow ______ 
Action Action Action Action
Take your preventer inhaler every day, even
when you are feeling well.
Your preventer inhaler 
is:__________________
Take your reliever inhaler if you have
symptoms.
Your reliever inhaler 
is:__________________
Use your reliever inhaler to relieve your 
symptoms and increase your preventer 
medication as described below:
Write the plan here: 
Once your symptoms or peak flow have
returned to normal or after a maximum of 14
days return to your normal treatment.
If your symptoms get worse follow Zone
3 instructions 
Continue taking your medicine as shown in
Zone 2.
Continue to take your reliever medicine when
needed. 
If you have been prescribed steroid tablets,
start taking them and let your doctor or
asthma nurse know within 24 hours 
If you have not been prescribed steroid 
tablets see a doctor or asthma nurse urgently
Take____5mg Predinisolone tablets 
immediately and again every morning
for______ days or until your symptoms have
improved and your peak flow is back to
normal (as in Zone 1). For you this means
______. 
1.Take one to two puffs of your reliever
inhaler (usually blue) 
2.Sit up and take slow steady breaths
3.If you don't feel better, continue to take
two puffs of your reliever inhaler every two 
minutes. You can take up to ten puffs 
4.If you do not feel better after taking your
reliever inhaler as above or if you are worried 
at any time call 999
5.If an ambulance does not arrive within 15
minutes, and you do not feel any better, 
repeat step 3 
If you are always in Zone 1, your doctor
or asthma nurse may want to reduce
your regular medicines.
Start to record your morning peak flow,
symptoms and medication in the study 
diary.
If you are in Zone 3 ask your doctor or
asthma nurse for an asthma review, 
even if you feel better. 
If your symptoms improve and you do
not need to call 999 you will need to see 
your doctor or asthma nurse within 24
hours 
Do not delay calling for help if your
asthma is getting worse, day or night
If you have stopped your treatment for 
any reason you should restart it at the 
first sign of asthma
Phone you research nurse to arrange a 
study visit.
Do not ignore worsening asthma. Get 
medical help
This information does not apply to
people using Symbicort SMART regime
who should discuss their advice with
their doctor or asthma nurse 
ZONE 1 ZONE 2 ZONE 3 ZONE 4 
Your asthma is under control if: 
• You have no or minimal symptoms during
the day and night (wheezing, coughing, 
shortness of breath or tightness in the
chest) 
• You can do all of your normal activities 
without asthma symptoms 
• Your peak flow reading is normal or near
normal for you: ______ 
Your asthma is getting worse if you have
ONE or MORE of the following:
• You need your reliever inhaler more than 
usual 
• You have more  difficulty sleeping because
of your asthma
• Your peak flow is below ______
Your asthma is much more severe if you 
have ONE or MORE of the following: 
• You need to take your reliever inhaler 
every four hours or more often 
• You are unable to manage your normal
activities 
• You have symptoms during the day or
night 
• Your peak flow reading is below_____ 
It is an asthma emergency if any of the 
following happen: 
• Your reliever inhaler (usually blue) does not 
help. 
• One or more of your symptoms get worse 
(wheezing, coughing, shortness of breath or
tightness in the chest)
• You are too breathless to speak 
• Your peak flow reading is below ______
Action Action Action Action
Take your preventer inhaler every day, even
when you are feeling well.
Your preventer inhaler 
is:__________________
Take your reliever inhaler if you have
symptoms.
Your reliever inhaler is:__________________
Use your reliever inhaler to relieve your
symptoms and continue your preventer 
medication at your normal dose.
If your symptoms get worse follow Zone
3 instructions 
Continue taking your medicine as shown in
Zone 2.
Continue to take your reliever medicine when
needed. 
If you have been prescribed steroid tablets,
start taking them and let your doctor or
asthma nurse know within 24 hours 
If you have not been prescribed steroid tablets 
see a doctor or asthma nurse urgently
Take___ 5mg Prednisolone tablets 
immediately and again every morning
for_____ days or until your symptoms have
improved and your peak flow is back to
normal (as in Zone 1). For you this means
______. 
If you do not improve with these tablets go to
Zone 4.
1. Take one to two puffs of your reliever
inhaler (usually blue) 
2. Sit up and take slow steady breaths
3. If you don't feel better, continue to
take two puffs of your reliever inhaler 
every two minutes. You can take up
to ten puffs 
4. If you do not feel better after taking
your reliever inhaler as above or if
you are worried at any time call 999 
5. If an ambulance does not arrive
within 15 minutes, and you do not 
feel any better, repeat step 3 
If you are always in Zone 1, your doctor
or asthma nurse may want to reduce your
regular medicines.
Start to record your morning peak flow,
symptoms and medication in the study 
diary.
If you are in Zone 3 ask your doctor or
asthma nurse for an asthma review, even
if you feel better. 
If your symptoms improve and you do not 
need to call 999 you will need to see your
doctor or asthma nurse within 24 hours 
Do not delay calling for help if your
asthma is getting worse, day or night
If you have stopped your treatment for 
any reason you should restart it at the 
first sign of asthma
Phone you research nurse to arrange a 
study visit.
Do not ignore worsening asthma. Get 
medical help
This information does not apply to people 
using Symbicort SMART regime who 
should discuss their advice with their 
doctor or asthma nurse 
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Appendix 5 Asthma diary cards
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Appendix 6 Baseline characteristics for
participants’ activation in zone 2 or above by
allocated intervention group
The baseline characteristics of the participants who activated zone 2 or above were well balancedbetween the usual-care and modified self-management groups (Table 35).
The mean age of participants was 57 years (SD 15.5 years) and 795 (71%) were female.
Of those participants who activated zone 2 or above, 811 (73%) were prescribed combination inhalers and
the majority of participants, 829 (74%), were on a low dose of maintenance steroid (≤ 1000 mcg/day
of BDP).
TABLE 35 Baseline characteristics for participants activating zone 2 (or above) by allocated intervention group
Characteristic
Intervention arm
Total with at least one
activation to zone 2 or
above (N= 1114)
Usual care (N= 552);
at least one activation
to zone 2 or above
Modified (N= 562);
at least one activation
to zone 2 or above
Age (years)
Mean (SD) 57.0 (15.4) 56.2 (15.5) 56.6 (15.5)
Min., max. 19, 94 16, 89 16, 94
Sex, n (% of total)
Male 154 (28) 165 (29) 319 (29)
Female 398 (72) 397 (71) 795 (71)
Recruited from
Primary care 426 (77) 453 (81) 879 (79)
Secondary care 126 (23) 109 (19) 235 (21)
PEF (l/minute) at screening
Mean (SD) 374.7 (111.2) 386.9 (116.5) 380.9 (114.0)
Type of inhaler, n (% of total)
Corticosteroid 162 (29) 141 (25) 303 (27)
Combination 390 (71) 421 (75) 811 (73)
Maintenance dose of inhaled corticosteroids (mcg/day of BDP)
Median (25th, 75th centiles) 800 (400, 1350) 800 (500, 1600) 800 (400, 1600)
Min., max. 100, 4000 80, 4000 80, 4000
Maintenance dose of steroids (used in randomisation stratification), n (% of total)
Low (≤ 1000 mcg/day of BDP) 413 (75) 416 (74) 829 (74)
High (> 1000 mcg/day of BDP) 139 (25) 146 (26) 285 (26)
continued
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TABLE 35 Baseline characteristics for participants activating zone 2 (or above) by allocated intervention group
(continued )
Characteristic
Intervention arm
Total with at least one
activation to zone 2 or
above (N= 1114)
Usual care (N= 552);
at least one activation
to zone 2 or above
Modified (N= 562);
at least one activation
to zone 2 or above
BTS step of asthma treatment, n (% of total)
Step 2 – regular preventer therapy 136 (25) 111 (20) 247 (22)
Step 3 – initial add-on therapy 213 (39) 195 (35) 408 (37)
Step 4 – persistent poor control 195 (35) 249 (44) 444 (40)
Step 5 – omalizumab 2 (0.4) 1 (0.2) 3 (0.3)
Not known 6 (1) 6 (1) 12 (1)
Smoking status, n (% of total)
Never 318 (58) 338 (60) 656 (59)
Current 36 (7) 29 (5) 65 (6)
Former 198 (36) 195 (35) 393 (35)
Pack-years for current or former smokers
n 234 224 458
Mean (SD) 14.2 (15.8) 12.9 (15.5) 13.6 (15.7)
Mini AQLQ overall score
n 551 557 1108
Mean (SD) 4.9 (1.2) 5 (1.2) 4.9 (1.2)
max., maximum; min., minimum.
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Appendix 7 Health economics and wider
societal costs
Wider societal costs
Only 41% of participants in both intervention groups reported their annual income and low numbers of
participants reported costs of travel; therefore, an available case has been explored in this analysis to make
the most of the available data. Table 36 shows the available cases for the number of days given up because
of illness and the mean travel times to GP or hospital appointments as reported in the questionnaire. Using
the participants’ number of GP visits and hospital outpatient visits, a mean total travel time per participant
for each kind of appointment was calculated. There was little difference between intervention groups in the
percentage of participants in paid employment (modified = 47% and usual care = 48% at 6 months). As for
productivity loss, when looking at both time points together, there was little difference in the mean number
of days given up as a result of respiratory illness between intervention groups.
Table 36 also shows how mean travel times to GP surgeries are mostly equal between groups at both time
points; however, the modified self-management group has a slightly lower mean travel time per participant
when the number of visits are taken into account, and both intervention groups have a lower travel time at
12 months. Once more, similar average travel times are seen for hospital outpatient visits and, when using
the number of visits, there was little difference between the intervention groups and follow-ups.
TABLE 36 Productivity loss and travel time
Productivity loss and travel
time
Time point
6 months 12 months
Usual care n Modified n Usual care n Modified n
Productivity loss
% in paid employment 48 675 47 695 47 615 43 614
% given up paid employment in
last 6 monthsa
4 321 12 329 3 286 4 266
Number of days given up,
mean (SD)
1.5 (9.2) 674 1.1 (7.7) 702 1.3 (10.6) 614 1.6 (11.9) 614
Number of hours given up by
family members, mean (SD)
0.12 (1.20) 432 0.24 (2.21) 427 0.32 (3.3) 406 0.28 (2.3) 401
Travel time
Mean travel time (minutes) to
GP surgery
22 (9.7) 734 21 (9.4) 742 21 (9.4) 667 22 (10.2) 652
Mean total travel time (minutes)
to GP surgery (calculated using
number of visits)
32 (78) 729 26 (53) 732 19 (38) 664 16 (34) 650
Mean travel time (minutes) to
hospital outpatient visit
34 (17) 734 36 (17) 742 35 (16) 665 37 (17) 650
Mean total travel time (minutes)
to hospital outpatient visit
(calculated using number of visits)
7 (31) 732 5 (28) 737 6 (24) 665 5 (21) 648
a Of those participants who said they were in paid employment.
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The mode of travel to the GP surgery was mostly equal between intervention groups at both 6 months
and 12 months, with car and walking the most popular methods. The majority of participants in both
intervention groups and at both time points reported taking 0–15 minutes to reach the GP surgery
[modified, 67% (6 months) and 64% (12 months); usual care, 61% (6 months) and 60% (12 months)].
Once again, the mode of transport to hospital outpatient visits was, on the whole, equally distributed
between the two intervention groups, with both groups reporting more bus use than when travelling to
the GP surgery. In both groups more participants reported having to travel for over 1 hour [modified, 15%
(6 months) and 21% (12 months); usual care, 13% (6 months) and 17% (12 months)]. The percentages
indicated the burden and time lost for travelling to hospital outpatient visits for both groups, as reflected
in Table 36. Table 37 shows the mean travel costs per participant as reported and then how this translated
into a total cost depending on their number of visits. The total travel costs are slightly greater for those
in the modified self-management group when both time points are considered. This is because one
participant in the modified self-management group reported very high costs for hospital outpatient visits.
A speculative estimate for the total cost at each follow-up time point has been calculated using productivity
loss resulting from time off work and time spent travelling to appointments, as well as the travel costs
reported in Table 37. However, the total numbers were very small because of the missing data. Table 38
shows the costs for the modified self-management group to be slightly higher than for the usual-care
group at both time points. To make the most of the available data, the analysis was also repeated using
the UK average wage rate (£31,800) to try and minimise the missing data caused by the poor report rate of
income.33 This resulted in a total of £220 (SD £1545, n = 487) for the usual-care group and £196 (SD £962,
n = 504) for the modified self-management group.
TABLE 38 Total societal costs
Societal cost (£)
Time point
6 months 12 months
Usual care (n= 256) Modified (n= 318) Usual care (n= 263) Modified (n= 327)
Total cost, mean (SD) 20 (59) 23 (66) 17 (53) 29 (137)
TABLE 37 Travel costs
Travel cost (£)
Time point
6 months 12 months
Usual care n Modified n Usual care n Modified n
GP travel cost, mean (SD) 1.33 (2.18) 520 1.22 (1.79) 531 1.24 (1.90) 460 1.12 (1.72) 450
Hospital travel cost, mean (SD) 4.00 (5.75) 501 3.79 (4.79) 515 4.14 (6.00) 434 3.83 (5.00) 437
GP visits × cost, mean (SD) 0.71 (2.49) 630 0.60 (2.04) 648 0.78 (4.10) 560 0.39 (1.71) 552
Hospital visits × cost, mean (SD) 0.53 (3.56) 679 0.91 (9.68) 708 0.28 (3.53) 610 0.72 (11.90) 608
Total travel cost, mean (SD) 1.23 (4.68) 678 1.56 (10.26) 682 1.12 (5.02) 597 1.08 (12.20) 583
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